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	 A	 series	 of	 new	 molecules	 having	 3‐(substituted)‐4,5,6,7‐tetrahydro‐6‐(substituted)‐1H‐
pyrazolo[3,4‐c]pyridine	 and	 3‐(substituted)‐5,6‐dihydro‐6‐(substituted)‐1H‐pyrazolo[3,4‐c]
pyridin‐7(4H)‐one	derivatives	were	designed	and	synthesized	 in	 large	scale	(grams	range).
The	structures	of	the	synthesized	compounds	were	elucidated	and	confirmed	by	1H	NMR,	13C
NMR,	 Mass	 spectra;	 and	 purity	 was	 also	 checked	 through	 LC/MS	 and	 HPLC	 analysis.	 The
antiproliferative	 activity	 of	 the	 compounds	 was	 checked	 for	 lung	 cancer,	 cervical	 cancer,
breast	cancer	and	prostate	cancer	on	panel	of	four	cell	lines.	A	few	compounds	(13c,	13g,	15g
and	15h)	 showed	promising	antiproliferative	activity	 in	 the	 range	of	5.12‐17.12	µM	which
were	 further	 tested	 for	 their	 inhibitory	activity	against	panel	of	8	human	kinases	at	10	µM
concentrations.	The	compounds	13c,	13g,	15g	and	15h	shows	prominent	 inhibitory	activity
against	Aurora‐A,	Aurora‐B,	CDK5/P25	and	mTOR	kinases.	
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1.	Introduction	
	
Cancer	 treatment	 is	difficult	due	 to	plethora	of	unwanted	
side	 effects	 [1].	 In	 present	 study,	 we	 have	 chosen	 4,5,6,7‐
tetrahydro‐1H‐pyrazolo[3,4‐c]pyridine	 and	 5,6‐dihydro‐1H‐
pyrazolo[3,4‐c]pyridin‐7(4H)‐one	as	core	structure	as	4,5,6,7‐
tetrahydro‐1H‐pyrazolo[3,4‐c]pyridine	 is	 showing	 diversified	
biological	activities	as	anticancer	activity	[2],	5‐HT6	 inhibitors	
for	 pain	 treatment	 [3],	 inflammatory	 disorders	 [4],	 GnRH	
receptor	 antagonists	 [5],	 kinase1	 inhibitors	 [6],	 cannabinoid	
receptors	[7],	inhibitor	of	blood	coagulation	factor	Xa	[8],	PDE4	
inhibitor	 [9],	 COX‐2	 inhibitors	 [10],	 antimicrobial	 [11]	 and	
P13K	 inhibitors	 [12].	 The	 pyrazole	 is	 known	 for	 adenine	
mimetic	pharmacophore	and	 is	useful	 in	 inhibitors	of	several	
classes	of	kinases	like	Aurora,	CDK‐2	and	MAP	kinases	as	these	
plays	 key	 role	 in	 drug	 discovery	 [2].	 The	 tetrahydro‐1H‐
pyrazole	 and	 their	 derivatives	 show	 diversifying	 activity.	 By	
considering	 their	 biological	 importance	 herein	we	 report	 the	
synthesis	of	3‐(substituted)‐4,5,6,7‐tetrahydro‐6‐(substitu‐
ted)‐1H‐pyrazolo[3,4‐c]pyridine	 and	 3‐(substituted)‐5,6‐di	
hydro‐6‐(substituted)‐1H‐pyrazolo[3,	 4‐c]pyridin‐7(4H)‐one	
and	anticancer	activity	in	cell	line	along	with	kinase	inhibition	
study.	 We	 have	 optimized	 routes	 for	 their	 synthesis.	 The	
synthetic	 methods	 adopted	 for	 the	 preparation	 of	 the	 title	
compounds	13a‐h	and	15a‐h	are	depicted	in	Schemes	1	and	2	
presented	below.	
	
2.	Experimental		
	
2.1.	Reagent	and	instrumentation	
	
All	chemicals,	unless	otherwise	specified,	were	purchased	
from	 commercial	 sources	 and	 were	 used	 without	 further	
purification.	The	major	chemicals	were	purchased	from	Sigma	
Aldrich	 and	 Avra	 Labs.	 The	 development	 of	 reactions	 was	
monitored	 by	 thin	 layer	 chromatography	 (TLC)	 analysis	 on	
Merck	pre‐coated	silica	gel	60	F254	aluminum	sheets,	visualized	
by	UV	 light.	All	 reactions	were	 carried	out	under	argon	 inert	
atmosphere.	 Melting	 points	 were	 recorded	 on	 SRS	 OptiMelt.	
The	purity	of	intermediates	was	pursued	by	TLC,	NMR,	and	LC‐
MS.	All	 final	 compounds	 and	 intermediates	 are	 characterized	
by	 NMR,	 LC‐MS	 and	 purity	 of	 final	 compounds	 pursued	 by	
HPLC	 and	 all	 structures	 are	 consistent	 with	 proposed	 struc‐
tures	characterization.	The	1H	NMR	spectra	were	recorded	on	
Varian	 NMR	 (400	 MHz)	 spectrometer.	 The	 13C	 NMR	 spectra	
were	recorded	on	Varian	NMR	(100	MHz)	spectrometer.		
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Reagents	and	conditions:	(a)	DMF‐DMA	at	100	°C,	1	h;	(b)	N2H4.H2O,	EtOH,	80	°C,	8	h;	(c)	(BOC)2O,	TEA,	DCM,	room	temperature,	3	h;	(d)	2	N	aq.	HCl,	room	
temperature,	2	h;	(e)	Pyridine	Br2,	THF,	room	temperature,	3	h;	(f)	2	N	NaOH,	100	°C,	3	h	(g)	benzyl	bromide,	2,6‐lutidine,	DMAP,	THF,	room	temperature,	8	h;	
(h)	Triflic	anhydride,	TEA,	DCM,	room	temperature,	6	h;	 (i)	Aromatic	boronic	acid,	Pd2(dba)3,	Ruphos,	Cs2CO3,	 toluene,	100	°C,	6	h,	 (general	procedure);	 (j)	
Pd/C,	H2,	MeOH,	50	psi,	room	temperature,	3	h	(general	procedure);	(k)	Alkyl	bromide,	2,6‐lutidine,	DMAP,	THF,	room	temperature,	8	h	(general	procedure);	(l)	
6	N	aq.	HCl,	room	temperature,	6	h	(general	procedure).	
	
Scheme	1	
	
	
The	chemical	shifts	are	reported	as	NMR	spectra	δppm	units.	
The	following	abbreviations	are	used;	singlet	(s),	doublet	(d),	
triplet	 (t),	 quartet	 (q),	 multiplet	 (m)	 and	 broad	 (br).	 Mass	
spectra	 were	 taken	 using	 Varian	 VG	 7070	 spectrometer	 at	
nominal	 5000	 resolution.	The	purity	 of	 final	 compounds	was	
determined	by	HPLC	on	an	Alltech	Alltima	C18	column	(3.2	×	
150	 mm,	 5	 µM)	 eluting	 with	 5‐80%	 acetonitrile	 /	 45	 nM	
sodium	bicarbonate.		
	
2.2.	Synthesis	
	
2.2.1.	Synthesis	of	tert‐butyl‐4‐((dimethylamino)methyl	
ene)‐3‐oxopiperidine‐1‐carboxylate	(2),	Step	(a)	
	
To	 a	 stirred	 solution	 of	 N‐tert‐butoxycarbonyl‐3‐piperi‐
done	 (1)	 (10.0	 g,	 50.2	 mmol)	 in	 N,N‐dimethylformamide	
dimethylacetal	 (50	mL).	 The	 reaction	mixture	was	 heated	 at	
100	°C	for	1	h.	Progress	of	reaction	was	monitored	by	LC/MS	
for	the	consumption	of	starting	material.	After	completion	the	
reaction,	the	reaction	mixture	cooled	to	room	temperature	and	
evaporated	 under	 reduced	pressure	 to	 obtain	 yellow	 gummy	
material.	The	obtained	crude	was	diluted	it	with	H2O	(100	mL)	
and	extracted	it	with	EtOAc	(2	×	50	mL).	The	organic	layer	was	
washed	 with	 H2O	 (50	mL)	 and	 brine	 (50	 mL),	 dried	 it	 over	
anhydrous	Na2SO4	 to	 obtain	yellow	solid.	 The	 crude	material	
was	 washed	 with	 10%	 ethyl	 acetate:hexane	 (v:v,	 10:90,	 100	
mL),	 hexane	 (100	mL)	 and	 diethyl	 ether	 (100	mL)	 to	 obtain	
compound	2.	 Color:	Yellow.	Yield:	78	%	 (10.0	g).	M.p.:	48‐49	
°C.	 1H	NMR	(400	MHz,	DMSO‐d6,	 δ,	 ppm):	1.41	 (sS,	9H,	 t‐Bu),	
2.22	(d,	2H,	J	=	6.4	Hz,	CH2),	2.44	(s,	6H,	N‐(CH3)2),	2.81	(m,	2H,	
CH2),	3.81	 (s,	 2H,	NH‐CH2),	6.89	 (s,	 1H,	N‐CH).	 13C	NMR	 (100	
MHz,	 CDCl3,	 δ,	 ppm):	 28.55,	 30.32,	 43.47,	 47.46,	 58.89,	 81.2,	
101.21,	 146.12,	 154.42,	 192.22.	 LC‐MS	 (EI,	m/z):	 255	 (M+H).	
Anal.	calcd.	for	C13H22N2O3:	C,	61.39;	H,	8.72;	N,	11.01.	Found:	
C,	61.36;	H,	8.73;	N,	11.03%.	
	
2.2.2.	Synthesis	of	4,5,6,7‐tetrahydro‐1H‐pyrazolo[4,3‐c]	
pyridine	(3),	Step	(b)	
	
To	a	 stirred	 solution	of	 compound	2	 (10.0	 g,	 39.4	mmol)	
was	dissolved	in	ethanol	(50	mL)	and	hydrazine	hydrate	(3.94	
g,	78.7	mmol).	The	reaction	mixture	was	heated	at	80	°C	for	8	
h	and	the	progress	of	reaction	was	monitored	by	LC‐MS	for	the	
consumption	of	starting	material.		
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Reagents	and	conditions:	(a)	KMnO4,	18‐Crown‐6,	DCM,	room	temperature,	6	h,	(general	procedure);	(b)	6	N	HCl,	room	temperature,	6	h	(general	procedure).
	
Scheme	2
	
	
The	reaction	mixture	was	cooled	to	room	temperature	and	
evaporated	 under	 reduced	pressure	 to	 obtain	 yellow	 gummy	
material.	 The	 obtained	 crude	material	 was	 purified	 by	 silica	
gel	(100‐200	mesh)	column	chromatography	by	using	10‐40%	
ethyl	 acetate:hexane	 (v:v,	 10‐40:90‐60).	 The	 obtained	
compound	was	washed	with	diethyl	ether	(100	mL)	to	obtain	
compound	3	[13].	Color:	Yellow.	Yield:	68.3%,	6	g.	M.p.:	74‐75	
°C.	 1H	NMR	 (400	MHz,	 DMSO‐d6,	 δ,	 ppm):	 1.46	 (s,	 9H,	 t‐Bu),	
2.22	(d,	2H,	J	=	6.4	Hz,	CH2),	2.80	(m,	2H,	CH2),	3.84	(s,	2H,	NH‐
CH2),	 7.31	 (s,	 1H,	 Ar‐H),	 12.6	 (br,	 1H,	 Ar‐NH).	 13C	NMR	 (100	
MHz,	 DMSO‐d6,	 δ,	 ppm):	 19.21,	 28.88,	 38.41,	 47.11,	 80.2,	
114.12,	 133.57,	 142.26,	 152.88.	 LC‐MS	 (EI,	m/z):	 225	 (M+H).	
Anal.	calcd.	for	C11H17N3O2:	C,	59.17;	H,	7.67;	N,	18.82.	Found:	
C,	59.14;	H,	7.68;	N,	18.80%.	
	
2.2.3.	Synthesis	of	di‐tert‐butyl	4,5‐dihydro‐7H‐pyrazolo	
[3,4‐c]pyridine‐1,6‐dicarboxylate	(4),	Step	(c)	
	
To	a	stirred	solution	of	compound	3	(5.00	g,	22.4	mmol)	in	
DCM	(50	mL),	 triethylamine	(6.00	ml,	44.8	mmol)	was	added	
BOC	 anhydride	 (7.33	 g,	 33.6	 mmol)	 and	 stirred	 reaction	
mixture	to	room	temperature	for	3	h.	Progress	of	reaction	was	
monitored	by	LC‐MS	for	the	consumption	of	starting	material.	
After	completion	the	reaction,	the	reaction	mixture	evaporated	
under	reduced	pressure	to	obtain	yellow	gummy	material.	The	
obtained	 crude	 was	 washed	 with	 10%	 ethyl	 acetate:hexane	
(v:v,	 10:90)	 (25	 mL),	 hexane	 (50	 mL)	 and	 diethyl	 ether	 (50	
mL)	 to	obtain	 compound	4.	 Color:	 Yellow.	Yield:	91	%,	6.6	 g.	
M.p.:	55‐56	°C.	 1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	1.56	(s,	
18H,	N‐(t‐Bu)2),	2.21	(d,	2H,	J	=	6.2	Hz,	CH2),	2.79	(m,	2H,	CH2),	
3.83	 (s,	 2H,	 N‐CH2),	 7.31	 (s,	 1H,	 Ar‐H).	 13C	 NMR	 (100	 MHz,	
CDCl3,	δ,	ppm):	21.92,	28.41,	31.32,	44.38,	77.2,	116.6,	135.23,	
143.84,	 148.66.	 LC‐MS	 (EI,	m/z):	 325	 (M+H).	 Anal.	 calcd.	 for	
C16H25N3O4:	 C,	 59.42;	 H,	 7.79;	 N,	 12.99.	 Found:	 C,	 59.40;	 H,	
7.80;	N,	12.97%.	
	
2.2.4.	Synthesis	tert‐butyl	4,5,6,7‐tetrahydropyrazolo[3,4‐c]	
pyridine‐1‐carboxylate	(5),	Step	(d)	
	
To	a	stirred	solution	compound	4	(6.50	g,	20.1	mmol)	was	
dissolved	 in	2	N	HCl	 (65	mL)	and	stirred	reaction	mixture	 to	
room	temperature	for	2	h.	Progress	of	reaction	was	monitored	
by	 LC‐MS	 for	 the	 consumption	 of	 starting	 material.	 After	
completion	 the	 reaction,	 the	 reaction	 mixture	 evaporated	
under	reduced	pressure	to	obtain	yellow	gummy	material.	The	
obtained	 crude	 was	 washed	 with	 10%	 ethyl	 acetate:hexane	
(v:v,10:90,	25	mL),	hexane	(50	mL)	and	diethyl	ether	(50	mL)	
to	obtain	compound	5.	Color:	Yellow.	Yield:	89.3	%,	4	g.	M.p.:	
61‐62	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	1.56	(s,	9H,	N‐
t‐Bu),	2.21	(d,	2H,	 J	=	6.2	Hz,	CH2),	2.78	(m,	2H,	CH2),	3.83	(s,	
2H,	 N‐CH2),	 7.31	 (s,	 1H,	 Ar‐H).	 13C	 NMR	 (100	MHz,	 CDCl3,	 δ,	
ppm):	12.26,	28.85,	31.52,	44.28,	78.84,	98.62,	134.36,	144.18,	
148.77.	 LC‐MS	 (EI,	 m/z):	 225	 (M+H).	 Anal.	 calcd.	 for	
C11H17N3O2:	 C,	 59.17;	 H,	 7.67;	 N,	 18.82.	 Found:	 C,	 59.19;	 H,	
7.64;	N,	18.80%.	
	
2.2.5.	Synthesis	tert‐butyl	3‐bromo‐4,5,6,7‐tetrahydro	
pyrazolo[3,4‐c]pyridine‐1‐carboxylate	(6),	Step	(e)		
	
To	a	 stirred	 solution	 compound	5	 (4.00	 g,	 17.9	mmol)	 in	
THF	(40	mL)	was	added	pyridine	hydrobromide	(5.74	g,	35.8	
mmol)	drop	wise	at	0	°C.	The	reaction	mixture	was	stirred	at	
room	temperature	for	3	h.	Progress	of	reaction	was	monitored	
by	LC‐MS	for	the	consumption	of	starting	material.	After	comp‐
letion	 the	 reaction,	 the	 reaction	 mixture	 evaporated	 under	
reduced	 pressure	 to	 obtain	 yellow	 gummy	 material.	 The	
obtained	 crude	 was	 washed	 with	 10%	 ethyl	 acetate:hexane	
(v:v,	 10:	 90,	 25	 mL),	 hexane	 (50	 mL),	 and	 diethyl	 ether	 (50	
mL),	 to	 obtain	 compound	6.	 Color:	 Yellow.	 Yield:	 92	%,	 5	 g.	
M.p.:	145‐146	 °C.	 1H	NMR	 (400	MHz,	DMSO‐d6,	 δ,	ppm):	1.39	
(s,	9H,	N‐t‐Bu),	2.49	(d,	2H,	J	=	6.2	Hz,	CH2),	2.88	(m,	2H,	CH2),	
3.79	(s,	2H,	N‐CH2).	13C	NMR	(100	MHz,	CDCl3,	δ,	ppm):	14.33,	
28.41,	30.76,	4312,	78.81,	115.61,	123.10,	139.18,	148.88.	LC‐
MS	 (EI,	 m/z):	 303	 (M+H).	 Anal.	 calcd.	 for	 C11H16BrN3O2:	 C,	
47.72;	H,	5.34;	N,	13.91.	Found:	C,	47.73;	H,	5.32;	N,	13.90%.	
	
2.2.6.	Synthesis	tert‐butyl	4,5,6,7‐tetrahydro‐3‐hydroxy	
pyrazolo[3,4‐c]pyridine‐1‐carboxylate	(7),	Step	(f)	
	
To	a	stirred	solution	compound	6	(5.00	g,	16.5	mmol)	in	2	
N	NaOH	(50	mL)	and	heat	reaction	mixture	to	100	°C	for	3	h.	
Progress	 of	 reaction	 was	 monitored	 by	 LC‐MS	 for	 the	 con‐
sumption	 of	 starting	material.	 After	 completion	 the	 reaction,	
the	 reaction	 mixture	 evaporated	 under	 reduced	 pressure	 to	
obtain	 yellow	 gummy	 material.	 The	 obtained	 crude	 was	
washed	 with	 10%	 ethyl	 acetate:hexane	 (v:v,	 10:90,	 50	 mL),	
hexane	(50	mL)	and	diethyl	ether	(50	mL)	to	obtain	compound	
7.	 Color:	Yellow.	Yield:	88.4	%,	3.5	g.	M.p.:	87‐88	 °C.	 1H	NMR	
(400	MHz,	DMSO‐d6,	δ,	ppm):	1.54	(s,	9H,	N‐t‐Bu),	2.20	(d,	2H,	J	
=	6.2	Hz,	CH2),	2.78	(m,	2H,	CH2),	3.79	(s,	2H,	N‐CH2).	13C	NMR	
(100	MHz,	 CDCl3,	 δ,	 ppm):	 12.23,	 28.41,	 31.76,	 44.36,	 78.88,	
99.10,	 134.17,	 144.16,	 147.46.	 LC‐MS	 (EI,	m/z):	 240	 (M+H).	
Anal.	calcd.	for	C11H17N3O3:	C,	55.22;	H,	7.16;	N,	17.56.	Found:	
C,	55.20;	H,	7.18;	N,	17.58%.	
	
2.2.7.	Synthesis	of	tert‐butyl	6‐benzyl‐4,5,6,7‐tetrahydro‐3‐
hydroxypyrazolo[3,4‐c]pyridine‐1‐carboxylate	(8),	Step	(g)	
	
To	a	stirred	solution	of	compound	7	(3.50	g,	14.6	mmol)	in	
THF	 (35	 mL)	 was	 added	 2,6‐lutidine	 (3.14	 g,	 29.3	 mmol),	
DMAP	(0.36	g,	2.93	mmol)	and	benzyl	bromide	(	2.98	g,	16.1	
mmol).	The	reaction	mixture	was	stirred	at	room	temperature	
for	6	h.	Progress	of	reaction	was	monitored	by	LC‐MS	for	the	
consumption	 of	 starting	 material.	 After	 completion	 the	
reaction,	 the	 reaction	 mixture	 evaporated	 under	 reduced	
pressure	 to	 obtain	 yellow	 gummy	 material.	 The	 obtained	
crude	was	washed	with	10%	ethyl	acetate:hexane	(v:v,	10:90,	
50	mL),	hexane	(	50	mL),	and	diethyl	ether	(50	mL),	to	obtain	
compound	8.	 Color:	Yellow.	Yield:	83	%,	4.5	 g.	M.p.:	 133‐134	
°C.	 1H	 NMR	 (400	MHz,	 DMSO‐d6,	 δ,	 ppm):	 1.42	 (s,	 9H,	 t‐Bu),	
2.34	 (d,	 2H,	 J	 =	 6.4	 Hz,	 CH2),	 2.68	 (m,	 2H,	 CH2),	 3.60	 (s,	 2H,	
CH2),	 3.70	 (s,	 2H,	 N‐CH2),	 7.38‐7.28	 (m,	 5H,	 Ar‐H).	 13C	 NMR	
(100	 MHz,	 CDCl3,	 δ,	 ppm):	 9.88,	 28.41,	 43.44,	 52.12,	 60.18,	
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78.81,	 98.67,	 127.62,	 128.21,	 128.34,	 128.46,	 128.58,	 135.11,	
135.21,	 144.66,	 148.78.	 LC‐MS	 (EI,	 m/z):	 330	 (M+H).	 Anal.	
calcd.	 for	 C18H23N3O3:	 C,	 65.63;	 H,	 7.04;	 N,	 12.76.	 Found:	 C,	
65.65;	H,	7.01;	N,	12.78%.	
	
2.2.8.	Synthesis	of	tert‐butyl	3‐(2,2,2‐trifluoroacetoyloxy)‐6‐
benzyl‐4,5,6,7‐tetrahydropyrazolo[3,4‐c]pyridine‐1‐
carboxylate	(9),	Step	(h)	
	
To	a	 stirred	solution	of	synthesis	of	 compound	8	 (3.50	g,	
10.6	 mmol)	 in	 DCM	 (35	 mL),	 triethylamine	 (2.12	 ml,	 15.9	
mmol)	was	added	triflouromethanesulfonicanhydride	(3.60	g,	
12.8	 mmol)	 drop	 wise	 at	 0	 °C.	 The	 reaction	 mixture	 was	
stirred	at	room	temperature	for	12	h.	Progress	of	reaction	was	
monitored	by	LC‐MS	for	the	consumption	of	starting	material.	
After	completion	the	reaction,	the	reaction	mixture	evaporated	
under	reduced	pressure	to	obtain	yellow	gummy	material.	The	
obtained	 crude	 was	 washed	 with	 10%	 ethyl	 acetate:hexane	
(v:v,	10:90,	50	mL),	hexane	(50	mL),	and	diethyl	ether	(50	mL),	
to	obtain	compound	9.	Color:	Yellow.	Yield:	88.5	%,	4	g.	M.p.:	
173‐174	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	1.40	(s,	9H,	
t‐Bu),	2.34	(d,	2H,	 J	=	6.4	Hz,	CH2),	2.68	(m,	2H,	CH2),	3.60	(s,	
2H,	CH2),	3.70	(s,	2H,	N‐CH2),	7.38‐7.28	(m,	5H,	Ar‐H).	13C	NMR	
(100	 MHz,	 CDCl3,	 δ,	 ppm):	 9.86,	 28.41,	 43.44,	 52.12,	 60.18,	
78.80,	 98.68,	 112.13,	 127.72,	 128.22,	 128.32,	 128.46,	 128.58,	
135.13,	135.22,	144.66,	148.78,	168.34.	LC‐MS	 (EI,	m/z):	426	
(M+H).	Anal.	calcd.	for	C20H22F3N3O4:	C,	56.47;	H,	5.21;	N,	9.88.	
Found:	C,	56.44;	H,	5.20;	N,	9.90%.	
	
2.2.9.	General	procedure	for	synthesis	of	compounds	10a‐d,	
Step	(i)	
	
To	a	stirred	solution	of	compound	9	 (1	mmol)	 in	 toluene	
(5	 mL)	 was	 substituted	 aromatic	 boronic	 acid	 (2	 mmol),	 2‐
dicyclohexylphosphino‐2,6‐diisopropoxybiphenyl	 (0.2	 mmol),	
cesium	 carbonate	 (3	 mmol)	 and	 tris(dibenzylideneacetone)	
dipalladium(0)	 (0.2	mmol).	The	 reaction	mixture	was	purged	
with	argon	for	10	min	and	heat	reaction	mixture	to	100	°C	for	
6	 h.	 Progress	 of	 reaction	 was	 monitored	 by	 LC‐MS.	 After	
completion	 the	 reaction,	 the	 reaction	 mixture	 was	 filtered	
through	 a	 pad	 of	 celite,	 washed	 with	 EtOAc	 (10	 mL)	 and	
saturated	cold	sodium	chloride	solution	(2×5	mL)	and	organic	
layer	was	evaporated	under	reduced	pressure	to	obtain	crude	
gummy	material	(10a‐d).	The	obtained	crude	was	purified	by	
silica	 gel	 (230‐400	 mesh)	 by	 using	 ethyl	 acetate:heptane	
(15:85,	v:v)	to	obtain	compound	10a‐d.	
Tert‐butyl	3‐(benzofuran‐2‐yl)‐6‐benzyl‐4,	5,	6,	7‐tetrahydro	
pyrazolo[3,4‐c]pyridine‐1‐carboxylate	 (10a):	 Color:	 Brown.	
Yield:	83%.	M.p.:	131‐132	°C.	 1H	NMR	(400	MHz,	DMSO‐d6,	δ,	
ppm):	1.38	(s,	9	H,	t‐Bu),	2.33	(d,	2H,	J	=	6.4	Hz,	CH2),	2.67	(m,	
2H,	CH2),	3.60	(s,	2H,	CH2),	3.71	(s,	2H,	N‐CH2),	6.65	(s,	1H,	Ar‐
H),	 7.13	 (m,	 1H,	Ar‐H),	 7.18	 (m,	 1H,	Ar‐H),	 7.38‐7.28	 (m,	7H,	
Ar‐H).	LC‐MS	(EI,	m/z):	430	(M+H).	Anal.	calcd.	for	C26H27N3O3:	
C,	72.71;	H,	6.34;	N,	9.78.	Found:	C,	72.70;	H,	6.36;	N,	9.75%.		
Tert‐butyl	3‐(benzo[b]thiophen‐2‐yl)‐6‐benzyl‐4,	5,	6,7‐tetra	
hydropyrazolo[3,4‐c]pyridine‐1‐carboxylate	 (10b):	 Color:	
Brown.	 Yield:	 81%.	 M.p.:	 145‐146	 °C.	 1H	 NMR	 (400	 MHz,	
DMSO‐d6,	 δ,	 ppm):	 1.39	 (s,	 9H,	 t‐Bu),	 2.33	 (d,	 2H,	 J	 =	 6.4	Hz,	
CH2),	 2.68	 (m,	2H,	 CH2),	 3.61	 (s,	 2H,	 CH2),	 3.7	 (s,	 2H,	N‐CH2),	
7.25	 (s,	1H,	Ar‐H),	7.38‐7.28	 (m,	7H,	Ar‐H),	7.68‐7.81	 (m,	2H,	
Ar‐H).	 LC‐MS	 (EI,	 m/z):	 446	 (M+H).	 Anal.	 calcd.	 for	 C26H27	
N3O2S:	 C,	 70.09;	H,	 6.11;	N,	9.43.	 Found:	 C,	 70.06;	H,	 6.13;	N,	
9.41%.	
Tert‐butyl	 6‐benzyl‐4,5,6,7‐tetrahydro‐3‐(quinolin‐3‐yl)pyra	
zolo[3,4‐c]pyridine‐1‐carboxylate	 (10c):	 Color:	 Brown.	 Yield:	
63%.	M.p.:	154‐155	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	
1.39	 (s,	 9H,	 t‐Bu),	 2.35	 (d,	 2H,	 J	 =	 6.4	Hz,	 CH2),	 2.67	 (m,	 2H,	
CH2),	3.61	 (s,	2H,	CH2),	3.70	(s,	2H,	N‐CH2),	7.38‐7.28	(m,	5H,	
Ar‐H),	 7.66‐7.45	 (m,	 3H,	Ar‐H),	8.19‐8.02	 (m,	 2H,	Ar‐H),	8.78	
(s,	 1H,	 Ar‐H).	 LC‐MS	 (EI,	 m/z):	 441	 (M+H).	 Anal.	 calcd.	 for	
C27H28N4O2:	 C,	 73.61;	 H,	 6.41;	 N,	 12.72.	 Found:	 C,	 73.64;	 H,	
6.39;	N,	12.74%.	
Tert‐butyl	 6‐benzyl‐4,5,6,7‐tetrahydro‐3‐(quinolin‐5‐yl)pyra	
zolo[3,4‐c]pyridine‐1‐carboxylate	 (10d):	 Color:	 Brown.	 Yield:	
66%.	M.p.:	161‐162	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	
1.39	 (s,	 9H,	 t‐Bu),	 2.33	 (d,	 2H,	 J	 =	 6.4	Hz,	 CH2),	 2.68	 (m,	 2H,	
CH2),	3.61	(s,	2H,	CH2),	3.70	(s,	2H,	N‐CH2),	7.38‐7.21	 (m,	5H,	
Ar‐H),	 7.66‐7.45	 (m,	 3H,	Ar‐H),	 8.19‐8.02	 (m,	 2H,	 Ar‐H),	8.78	
(s,	 1H,	 Ar‐H).	 LC‐MS	 (EI,	m/z):	 441	 (M+H).	 Anal.	 calcd.	 for	
C27H28N4O2:	 C,	 73.61;	 H,	 6.41;	 N,	 12.72.	 Found:	 C,	 73.63;	 H,	
6.42;	N,	12.73%.	
	
2.2.10.	General	procedure	for	synthesis	of	compounds	(11a‐
d),	Step	(j)	
	
To	 a	 stirred	 solution	 of	 compounds	 10a‐d	 (1	 mmol)	 in	
methanol	(10	mL)	was	added	palladium	on	carbon	(10	mol%)	
and	 keep	 the	 reaction	 in	 Parr	 Shaker	 apparatus	 by	 applying	
hydrogen	gas	pressure	of	50	psi	for	3	h	at	room	temperature.	
Progress	 of	 reaction	 was	 monitored	 by	 LC‐MS	 for	 the	 con‐
sumption	 of	 starting	material.	 After	 completion	 the	 reaction,	
the	 reaction	 mixtures	 filtered	 through	 a	 pad	 of	 celite	 and	
obtain	 filtrate	 evaporated	 under	 reduced	 pressure	 to	 obtain	
crude	 semisolid	material	 for	 compound	11a‐h.	 The	 obtained	
crude	was	washed	with	cold	pentane	and	cold	diethyl	ether	to	
obtain	solid	compounds	11a‐h.		
Tert‐butyl	3‐(benzofuran‐2‐yl)‐4,	5,	6,	7‐tetrahydropyrazolo	
[3,4‐c]pyridine‐1‐carboxylate	 (11a):	Color:	Brown.	Yield:	87%.	
M.p.:	115‐116	 °C.	 1H	NMR	 (400	MHz,	DMSO‐d6,	 δ,	ppm):	1.39	
(s,	 9H,	 t‐Bu),	 2.33	 (d,	2H,	 J	 =	6.4	Hz,	CH2),	 2.67	 (m,	2H,	CH2),	
3.60	(s,	2H,	N‐CH2),	6.65	(s,	1H,	Ar‐H),	7.13	(m,	1H,	Ar‐H),	7.18	
(m,	1H,	Ar‐H),	 7.38‐7.28	 (m,	2H,	Ar‐H).	 LC‐MS	 (EI,	m/z):	 340	
(M+H).	Anal.	calcd.	for	C19H21N3O3:	C,	67.24;	H,	6.24;	N,	12.38.	
Found:	C,	67.22;	H,	6.21;	N,	12.39%.	
Tert‐butyl	 3‐(benzo[b]thiophen‐2‐yl)‐4,	 5,	 6,	 7‐tetrahydro	
pyrazolo[3,4‐c]pyridine‐1‐carboxylate	 (11b):	 Color:	 Yellow.	
Yield:	90%.	M.p.:	121‐122	°C.	 1H	NMR	(400	MHz,	DMSO‐d6,	δ,	
ppm):	1.39	(s,	9H,	t‐Bu),	2.33	(d,	2H,	J	=	6.4	Hz,	CH2),	2.68	(m,	
2H,	CH2),	3.61	(s,	2H,	N‐CH2),	7.25	(s,	1H,	Ar‐H),	7.38‐7.24	(m,	
2H,	 Ar‐H),	 7.68‐7.81	 (m,	 2H,	 Ar‐H).	 LC‐MS	 (EI,	 m/z):	 356	
(M+H).	Anal.	calcd.	for	C19H21N3O2S:	C,	64.20;	H,	5.95;	N,	11.82.	
Found:	C,	64.18;	H,	5.96;	N,	11.84%.	
Tert‐butyl	4,5,6,7‐tetrahydro‐3‐(quinolin‐3‐yl)pyrazolo[3,	4‐
c]pyridine‐1‐carboxylate	(11c):	Color:	Yellow.	Yield:	86%.	M.p.:	
138‐139	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	1.39	(s,	9H,	
t‐Bu),	2.35	(2H,	d,	 J	=	6.4	Hz,	CH2),	2.66	(m,	2H,	CH2),	3.61	(s,	
2H,	N‐CH2),	7.66‐7.45	 (m,	3H,	Ar‐H),	8.19‐8.02	 (m,	2H,	Ar‐H),	
8.78	(s,	1H,	Ar‐H).	LC‐MS	(EI,	m/z):	351	(M+H).	Anal.	calcd.	for	
C20H22N4O2:	 C,	 68.55;	 H,	 6.33;	 N,	 15.99.	 Found:	 C,	 68.56;	 H,	
6.34;	N,	15.97%.	
Tert‐butyl	4,5,6,7‐tetrahydro‐3‐(quinolin‐5‐yl)pyrazolo[3,	4‐
c]pyridine‐1‐carboxylate	(11d):	Color:	Yellow.	Yield:	84%.	M.p.:	
140‐141	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	1.39	(s,	9H,	
t‐Bu),	2.33	(d,	2H,	 J	=	6.4	Hz,	CH2),	2.68	(m,	2H,	CH2),	3.61	(s,	
2H,	N‐CH2),	7.66‐7.45	 (m,	3H,	Ar‐H),	8.19‐8.02	 (m,	2H,	Ar‐H),	
8.78	(s,	1H,	Ar‐H).	LC‐MS	(EI,	m/z):	351	(M+H).	Anal.	calcd.	for	
C20H22N4O2:	 C,	 68.55;	 H,	 6.33;	 N,	 15.99.	 Found:	 C,	 68.57;	 H,	
6.32;	N,	15.98%.	
	
2.2.11.	General	procedure	for	synthesis	of	compounds	(12a‐
h),	Step	(k)	
	
To	 a	 stirred	 solution	 of	 compounds	11a‐d	 (1	mmol)	was	
dissolved	in	THF	(10	mL).	Then,	added	2,6‐lutidine	(2	equiv.),	
DMAP	(0.2	equiv.)	and	benzyl	bromide	(1.2	equiv.)	and	stirred	
reaction	 mixture	 to	 room	 temperature	 for	 8	 h.	 Progress	 of	
reaction	 was	 monitored	 by	 LC‐MS	 for	 the	 consumption	 of	
starting	 material.	 After	 completion	 the	 reaction	 the	 reaction	
mixture	evaporated	under	reduced	pressure	 to	obtain	yellow	
gummy	material.	 The	 obtained	 crude	was	washed	with	 20%	
ethyl	acetate:hexane	(v:v,	20:80),	hexane	and	diethyl	ether	 to	
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obtain	 yellow	 semisolid	 compound.	 Crystallization	 of	 crude	
was	 done	 by	 using	 pentane	 and	 diethyl	 ether	 to	 obtain	 solid	
compounds	12a‐h.		
Tert‐butyl	3‐(benzofuran‐2‐yl)‐4,5,	6,	7‐tetrahydro‐6‐(3‐met	
hoxyphenyl)pyrazolo[3,4‐c]pyridine‐1‐carboxylate	(12a):	Color:	
Yellow.	 Yield:	 85	 %.	 M.p.:	 134‐135	 °C.	 1H	 NMR	 (400	 MHz,	
DMSO‐d6,	δ,	ppm):	1.38	(s,	9H,	t‐Bu),	2.84	(d,	2H,	J	=	8Hz,	CH2),	
3.62	(s,	2H,	CH2),	3.78	(s,	3H,	O‐CH3),	4.40	(d,	2H,	J	=7.8	Hz,	N‐
CH2),	 6.97	 (d,	 1H,	 J	 =7.8	 Hz,	 Ar‐H),	 7.18‐7.08	 (m,	 2H,	 Ar‐H),	
7.41‐7.21	(m,	3H,	Ar‐H),	7.46	(t,	1H,	J	=	7.6	Hz,	Ar‐H),	7.74‐7.61	
(m,	 2H,	 Ar‐H).	 LC‐MS	 (EI,	m/z):	 446	 (M+H).	 Anal.	 calcd.	 for	
C26H27N3O4:	C,	70.09;	H,	6.11;	N,	9.43.	Found:	C,	70.07;	H,	6.12;	
N,	9.44%.	
Tert‐butyl	3‐(benzo[b]thiophen‐2‐yl)‐4,	5,	6,	7‐tetrahydro‐6‐
(3‐methoxyphenyl)pyrazolo[3,4‐c]pyridine‐1‐carboxylate	(12b):	
Color:	 Yellow.	 Yield:	 88	 %.	 M.p.:	 144‐145	 °C.	 1H	 NMR	 (400	
MHz,	DMSO‐d6,	 δ,	 ppm):	 1.38	 (s,	 9H,	 t‐Bu),	 2.97‐2.81	 (m,	 2H,	
CH2),	3.63	(s,	2H,	CH2),	3.76	(s,	3H,	O‐CH3),	4.36	(d,	2H,	J	=	8.4	
Hz,	 N‐CH2),	 6.41	 (t,	 1H,	 J	 =	 7.6	 Hz,	 Ar‐H),	 6.54	 (s,	 1H,	 Ar‐H),	
6.62	(m,	1H,	Ar‐H),	7.18‐7.04	(m,	2H,	Ar‐H),	7.32‐7.18	(m,	2H,	
Ar‐H),	 7.73‐7.68	 (m,	 2H,	 Ar‐H).	 LC‐MS	 (EI,	m/z):	 462	 (M+H).	
Anal.	calcd.	for	C26H27N3O3S:	C,	67.66;	H,	5.90;	N,	9.10.	Found:	
C,	67.63;	H,	5.92;	N,	9.12%.	
Tert‐butyl	 4,5,6,7‐tetrahydro‐6‐(3‐methoxyphenyl)‐3‐(quino	
lin‐3‐yl)pyrazolo[3,4‐c]pyridine‐1‐carboxylate	 (12c):	 Color:	
White.	Yield:	91%.	M.p.:	147‐148	°C.	1H	NMR	(400	MHz,	DMSO‐
d6,	δ,	ppm):	1.38	(s,	9H,	t‐Bu),	2.92	(d,	2H,	J	=	8.2	Hz,	CH2),	3.61	
(t,	2H,	J	=	8.2	Hz,	CH2),	3.72	(s,	3H,	O‐CH3),	4.42	(s,	2H,	N‐CH2),	
6.44	(s,	1H,	Ar‐H),	6.56	(s,	1H,	Ar‐H),	6.64	(d,	1H,	J	=	7.6	Hz,	Ar‐
H),	7.18	(t,	1H,	J	=	7.8	Hz,	Ar‐H),	7.81‐7.55	(dd,	2H,	J	=	8.4	Hz,	
16.8	Hz,	Ar‐H),	8.08	(t,	2H,	J	=	8.2	Hz,	Ar‐H),	8.58	(s,	1H,	Ar‐H),	
9.38	 (s,	 1H,	 Ar‐H),	 9.20	 (s,	 1H,	 Ar‐H).	 LC‐MS	 (EI,	m/z):	 457	
(M+H).	Anal.	calcd.	for	C27H28N4O3:	C,	71.03;	H,	6.18;	N,	12.27.	
Found:	C,	71.01;	H,	6.20;	N,	12.26%.	
Tert‐butyl	 4,5,6,7‐tetrahydro‐6‐(3‐methoxyphenyl)‐3‐(quino	
lin‐5‐yl)pyrazolo[3,4‐c]pyridine‐1‐carboxylate	 (12d):	 Color:	
White.	Yield:	89%.	M.p.:	148‐149	°C.	1H	NMR	(400	MHz,	DMSO‐
d6,	 δ,	 ppm):	 1.38	 (s,	 9H,	 t‐Bu),	 3.01	 (s,	 2H,	 CH2),	 3.61	 (s,	 2H,	
CH2),	3.76	(s,	3H,	O‐CH3),	4.38	(d,	2H,	J	=	8	Hz,	N‐CH2),	6.38	(t,	
1H,	J	=	7.6	Hz,	Ar‐H),	6.60	(s,	1H,	Ar‐H),	6.66	(t,	1H,	J	=	7.6	Hz,	
Ar‐H),	7.16	(d,	1H,	 J	=	8.8	Hz,	Ar‐H),	7.78‐7.58	(m,	2H,	Ar‐H),	
8.18‐8.01	(m,	2H,	Ar‐H),	8.42	(s,	1H,	Ar‐H),	9.38	(s,	1H,	Ar‐H),	
9.20	(s,	1H,	Ar‐H).	LC‐MS	(EI,	m/z):	457	(M+H).	Anal.	calcd.	for	
C27H28N4O3:	 C,	 71.03;	 H,	 6.18;	 N,	 12.27.	 Found:	 C,	 71.02;	 H,	
6.19;	N,	12.26%.	
Tert‐butyl	 3‐(benzofuran‐2‐yl)‐4,5,6,7‐tetrahydro‐6‐(pyrimi	
din‐2‐yl)pyrazolo[3,4‐c]pyridine‐1‐carboxylate	 (12e):	 Color:	
White.	Yield:	86%.	M.p.:	155‐156	°C.	1H	NMR	(400	MHz,	DMSO‐
d6,	δ,	ppm):	1.38	(s,	9H,	t‐Bu),	2.86	(d,	2H,	J	=	8Hz,	CH2),	4.08	(s,	
2H,	 CH2),	 4.96	 (d,	 2H,	 J	 =	 7.8	 Hz,	 N‐CH2),	 6.60	 (s,	 1H,	 Ar‐H),	
7.18‐7.02	(d,	1H,	Ar‐H),	7.49‐7.20	(m,	2H,	Ar‐H),	7.76‐7.10	(m,	
2H,	 Ar‐H),	 8.42	 (s,	 2H,	 Ar‐H).	 LC‐MS	 (EI,	m/z):	 418	 (M+H).	
Anal.	calcd.	for	C23H23N5O3:	C,	66.17;	H,	5.55;	N,	16.78.	Found:	
C,	66.15;	H,	5.53;	N,	16.79%.	
Tert‐butyl	 3‐(benzo[b]thiophen‐2‐yl)‐4,5,6,7‐tetrahydro‐6‐
(pyrimidin‐2‐yl)pyrazolo[3,4‐c]pyridine‐1‐carboxylate	 (12f):	
Color:	White.	Yield:	84%.	M.p.:	154‐155	°C.	1H	NMR	(400	MHz,	
DMSO‐d6,	 δ,	 ppm):	 1.38	 (s,	 9H,	 t‐Bu),	 3.06	 (d,	 2H,	 J	 =	 8.2	Hz,	
CH2),	4.18	(s,	2H,	CH2),	4.96	(d,	2H,	J	=	7.6	Hz,	N‐CH2),	6.56	(s,	
1H,	 Ar‐H),	 7.16‐7.02	 (d,	 1H,	 Ar‐H),	 7.49‐7.14	 (m,	 2H,	 Ar‐H),	
7.86‐7.54	 (m,	 2H,	 Ar‐H),	 8.54	 (s,	 2H,	 Ar‐H).	 LC‐MS	 (EI,	m/z):	
434	 (M+H).	Anal.	 calcd.	 for	C23H23N5O2S:	 C,	 63.72;	H,	5.35;	N,	
16.15.	Found:	C,	63.71;	H,	5.37;	N,	16.16%.	
Tert‐butyl	4,5,6,7‐tetrahydro‐6‐(pyrimidin‐2‐yl)‐3‐(quinolin‐
3‐yl)pyrazolo[3,4‐c]pyridine‐1‐carboxylate	 (12g):	Color:	White.	
Yield:	84%.	M.p.:	165‐166	°C.	 1H	NMR	(400	MHz,	DMSO‐d6,	δ,	
ppm):	1.38	(s,	9H,	t‐Bu),	2.92	(d,	2H,	J	=	8.4	Hz,	CH2),	4.12	(q,	
2H,	J	=	8.4	Hz,	CH2),	4.94	(s,	2H,	N‐CH2),	6.72	(t,	1H,	J	=	7.6	Hz,	
Ar‐H),	7.74	(t,	1H,	J	=	8	Hz,	Ar‐H),	7.84	(t,	1H,	 J	=	8	Hz,	Ar‐H),	
8.12	(d,	1H,	J	=	7.8	Hz,	Ar‐H),	8.22	(d,	1H,	J	=	7.8	Hz,	Ar‐H),	8.42	
(d,	1H,	J	=	7.6	Hz,	Ar‐H),	8.56	(s,	1H,	Ar‐H),	9.38‐9.22	(br,	2H,	
Ar‐H).	LC‐MS	(EI,	m/z):	429	(M+H).	Anal.	calcd.	for	C24H24N4O2:	
C,	67.27;	H,	5.65;	N,	19.61.	Found:	C,	67.25;	H,	5.64;	N,	19.63%.	
Tert‐butyl	4,5,6,7‐tetrahydro‐6‐(pyrimidin‐2‐yl)‐3‐(quinolin‐
5‐yl)pyrazolo[3,4‐c]pyridine‐1‐carboxylate	 (12h):	 Color:	 Yel‐
low.	Yield:	93%.	M.p.:	161‐162	°C.	 1H	NMR	(400	MHz,	DMSO‐
d6,	δ,	ppm):	1.38	(s,	9H,	t‐Bu),	2.62	(t,	2H,	J	=	8.2	Hz,	CH2),	4.04	
(q,	2H,	J	=	8.2	Hz,	CH2),	4.98	(s,	2H,	N‐CH2),	6.66	(s,	1H,	Ar‐H),	
7.44	(br,	1H,	Ar‐H),	7.58	(d,	1H,	J	=	8	Hz,	Ar‐H),	7.83‐7.68	(m,	
2H,	Ar‐H),	8.23‐8.01	(m,	2H,	Ar‐H),	8.28	(s,	1H,	Ar‐H),	8.92	(s,	
1H,	 Ar‐H).	 LC‐MS	 (EI,	 m/z):	 429	 (M+H).	 Anal.	 calcd.	 for	
C24H24N4O2:	 C,	 67.27;	 H,	 5.65;	 N,	 19.61.	 Found:	 C,	 67.24;	 H,	
5.66;	N,	19.64%.	
	
2.2.12.	General	procedure	for	synthesis	of	compound	13a‐h,	
Step	(l)	
	
To	 a	 stirred	 solution	 of	 compounds	12a‐h	 (1	mmol)	was	
dissolved	 in	2	N	dioxane	 in	HCl	 (10	mL)	and	stirred	 reaction	
mixture	to	room	temperature	for	6	h.	Progress	of	reaction	was	
monitored	by	LC‐MS	for	the	consumption	of	starting	material.	
After	completion	the	reaction,	the	reaction	mixture	evaporated	
under	reduced	pressure	to	obtain	yellow	gummy	material.	The	
crude	 obtained	 was	 washed	 with	 10%	 ethyl	 acetate:hexane,	
hexane	and	diethyl	ether	to	obtain	crude	13a‐h	as	yellow	solid	
material.	 The	 crude	was	purified	by	 column	 chromatography	
(silica	gel,	230‐400	mesh)	by	using	25‐75%	ethyl	acetate	and	
hexane	to	obtain	desired	compounds	13a‐h	as	solid	materials.		
3‐(Benzofuran‐2‐yl)‐4,	5,	6,	7‐tetrahydro‐6‐(3‐methoxyphen	
yl)‐1H‐pyrazolo[3,4‐c]pyridine	(13a):	Color:	White.	Yield:	91%.	
M.p.:	155‐156	 °C.	 1H	NMR	 (400	MHz,	DMSO‐d6,	 δ,	ppm):	2.84	
(d,	2H,	J	=	8	Hz,	CH2),	3.62	(s,	2H,	CH2),	3.78	(s,	3H,	O‐CH3),	4.39	
(d,	2H,	J	=	7.8	Hz,	N‐CH2),	6.96	(d,	1H,	J	=	7.8	Hz,	Ar‐H),	7.2‐7.12	
(m,	2H,	Ar‐H),	7.36‐7.21	(m,	3H,	Ar‐H),	7.46	(t,	1H,	J	=	7.6	Hz,	
Ar‐H),	 7.74‐7.63	 (m,	 2H,	 Ar‐H),	 13.38	 (s,	 1H,	 NH).	 13C	 NMR	
(100	MHz,	 CDCl3,	 δ,	 ppm):	 10.34,	 48.55,	 51.72,	 55.85,	 97.56,	
103.11,	 103.21,	 106.81,	 111.12,	 121.18,	 122.34,	 123.76,	
124.44,	130.84,	135.67,	150.42,	150.67,	155.67,	161.82.	LC‐MS	
(EI,	m/z):	345	(M+H).	Anal.	calcd.	 for	C21H19N3O2:	C,	73.03;	H,	
5.54;	N,	12.17.	Found:	C,	73.05;	H,	5.53;	N,	12.15%.	HPLC:	r.t.	=	
5.68	min,	purity	=	98.3%.		
3‐(Benzo[b]thiophen‐2‐yl)‐4,5,	6,	7‐tetrahydro‐6‐(3‐methoxy	
phenyl)‐1H‐pyrazolo[3,4‐c]pyridine	(13b):	Color:	Yellow.	Yield:	
89%.	M.p.:	161‐162	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	
2.97‐2.81	(m,	2H,	CH2),	3.63	 (s,	2H,	CH2),	3.76	 (s,	3H,	O‐CH3),	
4.36	 (d,	 2H,	 J	 =	 8.4	Hz,	N‐CH2),	 6.38	 (t,	 1H,	 J	 =	7.6	Hz,	Ar‐H),	
6.55	(s,	1H,	Ar‐H),	6.63	(m,	1H,	Ar‐H),	7.18‐7.04	(m,	2H,	Ar‐H),	
7.32‐7.2	 (m,	 2H,	 Ar‐H),	 7.73‐7.68	 (m,	 2H,	 Ar‐H),	 13.4	 (s,	 1H,	
NH).	 13C	NMR	 (100	MHz,	CDCl3,	 δ,	 ppm):	10.24,	48.45,	51.62,	
55.85,	 97.66,	 102.11,	 102.21,	 106.81,	 111.2,	 120.18,	 122.34,	
123.66,	 124.44,	 130.84,	 135.66,	 150.32,	 150.67,	 154.67,	
161.72.	 LC‐MS	 (EI,	 m/z):	 361	 (M+H).	 Anal.	 calcd.	 for	
C21H19N3OS:	 C,	 69.78;	 H,	 5.30;	 N,	 11.63.	 Found:	 C,	 69.77;	 H,	
5.32;	N,	11.61%.	HPLC:	r.t.	=	9.21	min,	purity	=	99.5%.	
3‐(4,	5,	6,7‐Tetrahydro‐6‐(3‐methoxyphenyl)‐1H‐pyrazolo[3,	
4‐c]pyridin‐3‐yl)quinolone	 (13c):	 Color:	 Yellow.	 Yield:	 80%.	
M.p.:	179‐180	 °C.	 1H	NMR	 (400	MHz,	DMSO‐d6,	 δ,	ppm):	2.92	
(d,	2H,	J	=	8.2	Hz,	CH2),	3.61	(t,	2H,	J	=	8.2	Hz,	CH2),	3.72	(s,	3H,	
O‐CH3),	4.42	(s,	2H,	N‐CH2),	6.34	(s,	1H,	Ar‐H),	6.56	(s,	1H,	Ar‐
H),	6.64	(d,	1H,	J	=	7.6	Hz,	Ar‐H),	7.16	(t,	1H,	J	=	7.8	Hz,	Ar‐H),	
7.81‐7.59	(dd,	2H,	J	=	8.4	Hz,	16.8	Hz,	Ar‐H),	8.08	(t,	2H,	J	=	8.2	
Hz,	Ar‐H),	8.56	(s,	1H,	Ar‐H),	9.38	(s,	1H,	Ar‐H),	13.26	(br.	s,	1H,	
NH).	 13C	NMR	 (100	MHz,	 CDCl3,	 δ,	 ppm):	 12.72,	 49.24,	 52.46,	
55.46,	 97.8,	 103.21,	 106.67,	 127.34,	 127.84,	 128.22,	 128.42,	
128.88,	 129.42,	 129.41,	 130.71,	 130.85,	 145.21,	 148.73,	
150.65,	 162.10.	 LC‐MS	 (EI,	m/z):	 357	 (M+H).	 Anal.	 calcd.	 for	
C22H20N4O:	C,	74.14;	H,	5.66;	N,	15.72.	Found:	C,	74.17;	H,	5.65;	
N,	15.71%.	HPLC:	r.t.	=	4.89	min,	purity	=	96.6%.	
5‐(4,5,6,7‐Tetrahydro‐6‐(3‐methoxyphenyl)‐1H‐pyrazolo	 [3,	
4‐c]pyridin‐3‐yl)quinolone	 (13d):	Color:	Off	white.	Yield:	86%.	
M.p.:	184‐185	 °C.	 1H	NMR	 (400	MHz,	DMSO‐d6,	 δ,	ppm):	3.01	
(s,	2H,	CH2),	3.61	(s,	2H,	CH2),	3.76	(s,	3H,	O‐CH3),	4.39	(d,	2H,	J	
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=	8	Hz,	N‐CH2),	6.38	(t,	1H,	J	=	7.6	Hz,	Ar‐H),	6.58	(s,	1H,	Ar‐H),	
6.65	(t,	1H,	J	=	7.6	Hz,	Ar‐H),	7.16	(d,	1H,	J	=	8.8	Hz,	Ar‐H),	7.8‐
7.58	(m,	2H,	Ar‐H),	8.18‐8.01	(m,	2H,	Ar‐H),	8.43	(s,	1H,	Ar‐H),	
9.38	&	9.20	(s,	1H,	Ar‐H),	13.2	(br,	1H,	NH,	1H).	13C	NMR	(100	
MHz,	CDCl3,	δ,	ppm):	12.62,	49.34,	52.56,	54.46,	97.86,	102.21,	
106.77,	 127.44,	 127.84,	 128.32,	 128.42,	 128.88,	 129.42,	
129.40,	130.60,	130.85,	145.31,	148.63,	151.14,	162.60.	LC‐MS	
(EI,	m/z):	 357	 (M+H).	Anal.	 calcd.	 for	C22H20N4O:	 C,	 74.14;	H,	
5.66;	N,	15.72.	Found:	C,	74.11;	H,	5.69;	N,	15.71%.	HPLC:	r.t.	=	
5.09	min,	purity	=	98.0%.	
3‐(Benzofuran‐2‐yl)‐4,	5,	6,	7‐tetrahydro‐6‐(pyrimidin‐2‐yl)‐
1H‐pyrazolo[3,4‐c]pyridine	 (13e):	 Color:	 Yellow.	 Yield:	 88%.	
M.p.:	167‐168	 °C.	 1H	NMR	(400	MHz,	DMSO‐d6,	 δ,	ppm):	2.86	
(d,	2H,	J	=	8Hz,	CH2),	4.08	(s,	2H,	CH2),	4.96	(d,	2H,	J	=	7.8	Hz,	N‐
CH2),	6.65	(s,	1H,	Ar‐H),	7.16‐7.02	(d,	1H,	Ar‐H),	7.49‐7.21	(m,	
2H,	 Ar‐H),	 7.76‐7.6	 (m,	 2H,	 Ar‐H),	 8.42	 (s,	 2H,	 Ar‐H),	 13.4	 &	
12.9	(br.	s,	1H,	NH).	13C	NMR	(100	MHz,	CDCl3,	δ,	ppm):	10.41,	
48.67,	 51.72,	 102.82,	 103.03,	 110.62,	 111.67,	 121.12,	 123.46,	
123.86,	 135.40,	 144.20,	 150.66,	 162.84,	 175.88.	 LC‐MS	 (EI,	
m/z):	318	(M+H).	Anal.	calcd.	for	C18H15N5O:	C,	68.13;	H,	4.46;	
N,	22.07.	Found:	C,	68.11;	H,	4.48;	N,	22.09%.	HPLC:	r.t.	=	7.58	
min,	purity	=	93.7%.	
3‐(Benzo[b]thiophen‐2‐yl)‐4,	5,	6,7‐tetrahydro‐6‐(pyrimidin‐
2‐yl)‐1H‐pyrazolo[3,4‐c]pyridine	 (13f):	 Color:	 Yellow.	 Yield:	
91%.	M.p.:	197‐198	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	
3.06	(d,	2H,	J	=	8.2	Hz,	CH2),	4.18	(s,	2H,	CH2),	4.96	(d,	2H,	J	=	
7.6	Hz,	N‐CH2),	6.66	(s,	1H,	Ar‐H),	7.16‐7.04	(d,	1H,	Ar‐H),	7.49‐
7.17	(m,	2H,	Ar‐H),	7.86‐7.59	(m,	2H,	Ar‐H),	8.52	(s,	2H,	Ar‐H),	
13.4	&	12.0	(br.	s,	1H,	NH).	13C	NMR	(100	MHz,	CDCl3,	δ,	ppm):	
10.40,	 48.66,	 51.72,	 102.72,	 103.30,	 110.62,	 111.67,	 121.22,	
123.46,	123.72,	135.48,	144.20,	148.66,	162.84,	174.78.	LC‐MS	
(EI,	m/z):	 334	 (M+H).	 Anal.	 calcd.	 for	 C18H15N5S:	 C,	 64.84;	H,	
4.53;	N,	21.01.	Found:	C,	64.86;	H,	4.51;	N,	21.03%.	HPLC:	r.t.	=	
5.84	min,	purity	=	97.5%.	
3‐(4,5,6,7‐Tetrahydro‐6‐(pyrimidin‐2‐yl)‐1H‐pyrazolo[3,	4‐
c]pyridin‐3‐yl)quinolone	(13g):	Color:	White.	Yield:	76	%.	M.p.:	
185‐186	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	2.92	(d,	2H,	
J	 =	8.4	Hz,	 CH2),	 4.12	 (q,	 2H,	 J	 =	 8.4	Hz,	CH2),	 4.94	 (s,	 2H,	N‐
CH2),	6.7	(t,	1H,	 J	=	7.6	Hz,	Ar‐H),	7.74	(t,	1H,	 J	=	8	Hz,	Ar‐H),	
7.84	(t,	1H,	J	=	8	Hz,	Ar‐H),	8.14	(d,	1H,	J	=	7.8	Hz,	Ar‐H),	8.22	
(d,	1H,	J	=	7.8	Hz,	Ar‐H),	8.42	(d,	1H,	J	=	7.6	Hz,	Ar‐H),	8.58	(s,	
1H,	Ar‐H),	9.38‐9.22	(br,	2H,	Ar‐H),13.2	&	12.8	(br.	s,	1H,	NH).	
13C	NMR	(100	MHz,	CDCl3,	δ,	ppm):	12.76,	49.12,	52.46,	103.24,	
110.36,	 128.62,	 128.88,	 129.42,	 129.51,	 129.62,	 130.41,	
134.83,	 144.42,	 145.12,	 148.80,	 157.90,	 162.78.	 LC‐MS	 (EI,	
m/z):	329	(M+H).	Anal.	calcd.	for	C19H16N6:	C,	69.50;	H,	4.91;	N,	
25.59.	 Found:	 C,	 69.52;	 H,	 4.93;	 N,	 25.60%.	HPLC:	 r.t.	 =	 6.59	
min,	purity	=	95.8%.	
5‐(4,5,6,7‐Tetrahydro‐6‐(pyrimidin‐2‐yl)‐1H‐pyrazolo[3,	4‐
c]pyridin‐3‐yl)quinolone	(13h):	Color:	White.	Yield:	88	%.	M.p.:	
188‐189	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	2.62	(t,	2H,	J	
=	8.2	Hz,	CH2),	4.04	(q,	2H,	J	=	8.2	Hz,	CH2),	4.98	(s,	2H,	N‐CH2),	
6.63	(s,	1H,	Ar‐H),	7.44	(br,	1H,	Ar‐H),	7.68	(d,	1H,	J	=	8	Hz,	Ar‐
H),	 7.83‐7.68	 (m,	 2H,	Ar‐H),	 8.23‐8.01	 (m,	 2H,	Ar‐H),	 8.40	 (s,	
1H,	Ar‐H),	8.92	(s,	1H,	Ar‐H),	13.2	(br.	s,	1H,	NH).	13C	NMR	(100	
MHz,	 CDCl3,	 δ,	 ppm):	 15.55,	 49.33,	 53.66,	 110.21,	 116.68,	
119.7,	121.22,	125.58,	127.79,	129.10,	130.00,	130.42,	136.46,	
137.12,	147.45,	150.51,	159.12,	162.84.	LC‐MS	 (EI,	m/z):	329	
(M+H).	 Anal.	 calcd.	 for	 C19H16N6:	 C,	 69.50;	 H,	 4.91;	 N,	 25.59.	
Found:	 C,	 69.51;	 H,	 4.90;	 N,	 25.59%.	 HPLC:	 r.t.	 =	 4,78	 min,	
purity	=	99.2%.	
	
2.2.13.	General	procedure	for	synthesis	of	compounds	14a‐
h,	Step	(a)	
	
To	 a	 stirred	 solution	 of	 compounds	12a‐h	 (1	mmol)	was	
dissolved	 in	DCM	(10	mL).	Then	added	KMnO4	(2	equiv.)	and	
18‐crown‐6	(0.5	equiv.)	and	stirred	reaction	mixture	to	room	
temperature	 for	 6	 h.	 Progress	 of	 reaction	was	monitored	 by	
LC‐MS	 for	 the	 consumption	 of	 starting	material.	 After	 comp‐
letion	the	reaction,	the	reaction	mixture	was	diluted	with	DCM	
(10	mL)	 and	washed	 it	with	water	 (3×5	mL).	 Separated	 and	
collected	the	organic	 layer,	washed	 it	with	5	mL	of	brine	and	
dried	organic	 layer	over	anhydrous	Na2SO4	and	evaporated	it	
under	reduced	pressure	to	obtain	crude	compounds	14a‐h	as	
semisolid	 compound.	 The	 crude	 obtained	 was	 washed	 with	
5%	ethyl	 acetate:	hexane,	hexane	and	diethyl	 ether	 to	obtain	
yellow	 semisolid	 compound.	 The	 obtained	 compound	 was	
crystallized	 by	 using	 cold	 pentane	 and	 cold	 diethyl	 ether	 to	
obtain	solid	compounds	14a‐h.		
Tert‐butyl	 3‐(benzofuran‐2‐yl)‐4,5,6,7‐tetrahydro‐6‐(3‐met	
hoxyphenyl)‐7‐oxopyrazolo[3,4‐c]pyridine‐1‐carboxylate	 (14a):	
Color:	 Brown.	 Yield:	 75	 %.	 M.p.:	 165‐166	 °C.	 1H	 NMR	 (400	
MHz,	DMSO‐d6,	δ,	ppm):	1.41	(s,	9H,	 t‐Bu),	3.21	(t,	2H,	 J	=	7.6	
Hz,	2H,	CH2),	3.31	(s,	3H,	O‐CH3),	4.18	(d,	2H,	J	=	7.6	Hz,	N‐CH2),	
6.8	(d,	1H,	J	=	7.6	Hz,	Ar‐H),	6.87‐6.79	(m,	2H,	Ar‐H),	7.44‐7.21	
(m	 4H,	 Ar‐H),	 7.76‐7.6	 (m,	 2H,	 Ar‐H).	 LC‐MS	 (EI,	m/z):	 460	
(M+H).	 Anal.	 calcd.	 for	 C26H25N3O5:	 C,	 67.96;	H,	 5.48;	N,	 9.14.	
Found:	C,	67.98;	H,	5.47;	N,	9.15%.	
Tert‐butyl	3‐(benzo[b]thiophen‐2‐yl)‐4,	5,	6,	7‐tetrahydro‐6‐
(3‐methoxyphenyl)‐7‐oxopyrazolo[3,4‐c]pyridine‐1‐carboxylate	
(14b):	 Color:	 Brown.	 Yield:	 77%.	 M.p.:	 171‐172	 °C.	 1H	 NMR	
(400	MHz,	DMSO‐d6,	δ,	ppm):	1.41	(s,	9H,	t‐Bu),	3.40	(t,	2H,	J	=	
8.4	Hz,	CH2),	3.74	(s,	3H,	O‐CH3),	4.24	(d,	2H,	J	=	6.2	Hz,	N‐CH2),	
6.38	(d,	1H,	J	=	7.6	Hz,	Ar‐H),	6.54	(s,	1H,	Ar‐H),	6.63‐6.57	(m,	
2H,	Ar‐H),	7.2‐7.11	(m,	3H,	Ar‐H),	7.56‐7.44	(dd,	2H,	J	=	8.2	Hz,	
4.1	 Hz,	 Ar‐H).	 LC‐MS	 (EI,	m/z):	 476	 (M+H).	 Anal.	 calcd.	 for	
C26H25N3O4S:	C,	65.67;	H,	5.30;	N,	8.84.	Found:	C,	65.65;	H,	5.31;	
N,	8.83%.	
Tert‐butyl	4,	5,	6,	7‐tetrahydro‐6‐(3‐methoxyphenyl)‐7‐oxo‐
3‐(quinolin‐3‐yl)pyrazolo[3,4‐c]pyridine‐1‐carboxylate	 (14c):	
Color:	Brown.	Yield:	78%.	M.p.:	181‐182	°C.	1H	NMR	(400	MHz,	
DMSO‐d6,	δ,	ppm):	1.41	(s,	9H,	t‐Bu),	3.21	(br	s,	2H,	CH2),	3.83	
(s,	3H,	O‐CH3),	4.16	(s,	2H,	N‐CH2),	6.93	(d,	1H,	J	=	7.8	Hz,	Ar‐
H),	7.12	(d,	1H,	J	=	8	Hz,	Ar‐H),	7.18	(s,	1H,	Ar‐H),	7.42	(m,	1H,	
Ar‐H),	7.58	(t,	1H,	J	=	7.2	Hz,	Ar‐H),	7.72	(t,	1H,	J	=	7.2	Hz,	Ar‐
H),	7.84	(d,	1H,	J	=	7.6	Hz,	Ar‐H),	8.14	(d,	1H,	J	=	7.6	Hz,	Ar‐H),	
8.56	 (s,	 1H,	 Ar‐H),	 9.41	 (s,	 1H,	 Ar‐H).	 LC‐MS	 (EI,	m/z):	 471	
(M+H).	Anal.	calcd.	for	C27H26N4O4:	C,	68.92;	H,	5.57;	N,	11.91.	
Found:	C,	68.91;	H,	5.55;	N,	11.92%.		
Tert‐butyl	4,	5,	6,	7‐tetrahydro‐6‐(3‐methoxyphenyl)‐7‐oxo‐
3‐(quinolin‐5‐yl)pyrazolo[3,4‐c]pyridine‐1‐carboxylate	 (14d):	
Color:	Brown.	Yield:	76%.	M.p.:	188‐189	°C.	1H	NMR	(400	MHz,	
DMSO‐d6,	δ,	ppm):	1.41	(s,	9H,	t‐Bu),	3.75	(s,	3H,	O‐CH3),	3.80	
(d,	2H,	J	=	7.6	Hz,	CH2),	4.38	(d,	2H,	J	=	7.8	Hz,	N‐CH2),	6.34	(t,	
1H,	J	=	7.6	Hz,	Ar‐H),	6.68	(s,	1H,	Ar‐H),	6.75	(t,	1H,	J	=	7.8	Hz,	
Ar‐H),	7.14	(m,	1H,	Ar‐H),	7.88	(m,	1H,	Ar‐H),	8.14‐7.98	(m,	3H,	
Ar‐H),	8.37‐8.33	(d,	1H,	J	=	7.8	Hz,	Ar‐H),	9.16	(s,	1H,	Ar‐H).	LC‐
MS	(EI,	m/z):	471	(M+H).	Anal.	calcd.	for	C27H26N4O4:	C,	68.92;	
H,	5.57;	N,	11.91.	Found:	C,	68.93;	H,	5.55;	N,	11.92%.		
Tert‐butyl	3‐(benzofuran‐2‐yl)‐4,	5,	6,	7‐tetrahydro‐7‐oxo‐6‐
(pyrimidin‐2‐yl)pyrazolo[3,4‐c]pyridine‐1‐carboxylate	 (14e):	
Color:	White.	Yield:	77%.	M.p.:	163‐164	°C.	1H	NMR	(400	MHz,	
DMSO‐d6,	δ,	ppm):	1.41	(s,	9H,	t‐Bu),	3.22	(s,	2H,	CH2),	4.24	(d,	
2H,	 J	 =	8.2	Hz,	N‐CH2),	 7.41‐7.16	 (m	4H,	Ar‐H),	7.68‐7.54	 (m,	
2H,	Ar‐H),	8.84	(d,	2H,	J	=	7.8	Hz,	Ar‐H).	LC‐MS	(EI,	m/z):	431	
(M+H).	Anal.	calcd.	for	C23H21N5O4:	C,	64.03;	H,	4.91;	N,	16.23.	
Found:	C,	64.02;	H,	4.94;	N,	16.25%.	
Tert‐butyl	3‐(benzo[b]thiophen‐2‐yl)‐4,	5,	6,	7‐tetrahydro‐7‐
oxo‐6‐(pyrimidin‐2‐yl)pyrazolo[3,	 4‐c]pyridine‐1‐carboxylate	
(14f):	 Color:	 Brown.	 Yield:	 71	%.	 M.p.:	 155‐156	 °C.	 1H	 NMR	
(400	MHz,	 DMSO‐d6,	 δ,	 ppm):	 1.41	 (s,	 9H,	 t‐Bu),	 3.48	 (s,	 2H,	
CH2),	 4.44	 (d,	 2H,	 J	 =	8.2	Hz,	N‐CH2),	 7.48‐7.16	 (m	4H,	Ar‐H),	
7.78‐7.58	(m,	2H,	Ar‐H),	8.84	(d,	2H,	J	=	7.6	Hz,	Ar‐H).	LC‐MS	
(EI,	m/z):	448	(M+H).	Anal.	calcd.	for	C23H21N5O3S:	C,	61.73;	H,	
4.73;	N,	15.65.	Found:	C,	61.72;	H,	4.75;	N,	15.63%.	
Tert‐butyl	4,	5,	6,	7‐tetrahydro‐7‐oxo‐6‐(pyrimidin‐2‐yl)‐3‐
(quinolin‐3‐yl)pyrazolo[3,	 4‐c]pyridine‐1‐carboxylate	 (14g):	
Color:	 Brown.	 Yield:	 76	 %.	 M.p.:	 161‐162	 °C.	 1H	 NMR	 (400	
MHz,	DMSO‐d6,	δ,	ppm):	1.41	(s,	9H,	t‐Bu),	3.26	(q,	2H,	J	=	7.6	
Hz,	CH2),	4.26	(t,	2H,	J	=	7.6	Hz,	N‐CH2),	7.28	(t,	1H,	J	=	7.6	Hz,	
Ar‐H),	7.56	(q,	1H,	J	=	8.2	Hz,	Ar‐H),	7.82	(t,	1H,	J	=	8.2	Hz,	Ar‐
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H),	8.18‐8.02	(q,	2H,	Ar‐H),	8.60	(s,	1H,	Ar‐H),	8.83	(d,	2H,	Ar‐
H),	9.38	(s,	1H,	Ar‐H).	LC‐MS	(EI,	m/z):	443	(M+H).	Anal.	calcd.	
for	C24H22N6O3:	C,	65.15;	H,	5.01;	N,	18.99.	Found:	C,	65.14;	H,	
5.03;	N,	18.98%.	
Tert‐butyl	4,	5,	6,	7‐tetrahydro‐7‐oxo‐6‐(pyrimidin‐2‐yl)‐3‐
(quinolin‐5‐yl)pyrazolo[3,	 4‐c]pyridine‐1‐carboxylate	 (14h):	
Color:	Brown.	Yield:	73%.	M.p.:	164‐165	°C.	1H	NMR	(400	MHz,	
DMSO‐d6,	 δ,	 ppm):	1.41	 (s,	 9H,	 t‐Bu),	 2.8	 (q,	2H,	 CH2),	 4.2	 (q,	
2H,	N‐CH2),	7.26	(t,	1H,	J	=	7.2	Hz,	Ar‐H),	7.42	(d,	1H,	J	=	7.4	Hz,	
Ar‐H),	7.64	(d,	1H,	J	=	8	Hz,	Ar‐H),	7.82	(t,	1H,	J	=	7.6	Hz,	Ar‐H),	
8.12	(d,	2H,	J	=	7.4	Hz,	Ar‐H),	8.8	(d,	2H,	J	=	7.6	Hz,	Ar‐H),	8.96	
(s,	 1H,	 Ar‐H).	 LC‐MS	 (EI,	 m/z):	 443	 (M+H).	 Anal.	 calcd.	 for	
C24H22N6O3:	 C,	 65.15;	 H,	 5.01;	 N,	 18.99.	 Found:	 C,	 65.13;	 H,	
5.02;	N,	18.97%.	
	
2.2.14.	General	procedure	for	synthesis	of	compounds	15a‐
h,	Step	(b)	
	
To	 a	 stirred	 solution	 of	 compounds	14a‐h	 (1	mmol)	was	
dissolved	 in	2	N	dioxane	 in	HCl	 (10	mL)	and	stirred	 reaction	
mixture	to	room	temperature	for	6	h.	Progress	of	reaction	was	
monitored	by	LC‐MS	for	the	consumption	of	starting	material.	
After	completion	the	reaction,	the	reaction	mixture	evaporated	
under	reduced	pressure	to	obtain	yellow	gummy	material.	The	
obtained	 crude	was	washed	with	 10%	 ethyl	 acetate:	 hexane,	
hexane	and	diethyl	ether	to	obtain	crude	15a‐h	as	yellow	solid	
material.	 The	 obtained	 compound	 was	 purified	 by	 column	
chromatography	 by	using	 silica	 gel	 (230‐400	mesh)	by	using	
25‐75%	ethyl	acetate	and	hexane	to	obtain	desired	compound	
15a‐h	as	solid	materials.		
3‐(Benzofuran‐2‐yl)‐5,6‐dihydro‐6‐(3‐methoxyphenyl)‐1H‐
pyrazolo[3,4‐c]pyridin‐7(4H)‐one	 (15a):	 Color:	 White.	 Yield:	
87%.	M.p.:	191‐192	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	
3.21	(t,	2H,	J	=	7.6	Hz,	CH2),	3.31	(s,	3H,	O‐CH3),	4.18	(d,	2H,	J	=	
7.6	Hz,	N‐CH2),	6.82	(d,	1H,	J	=	7.6	Hz,	Ar‐H),	6.89‐6.79	(m,	2H,	
Ar‐H),	 7.40‐7.21	 (m	 4H,	 Ar‐H),	 7.76‐7.60	 (m,	 2H,	 Ar‐H),	 14.4	
(br,	1H,	NH).	13C	NMR	(100	MHz,	CDCl3,	δ,	ppm):	10.64,	51.82,	
55.85,	 97.46,	 103.31,	 103.61,	 106.61,	 111.02,	 121.18,	 122.34,	
123.76,	 124.44,	 128.84,	 134.67,	 150.42,	 150.67,	 156.61,	
156.88,	 161.72.	 LC‐MS	 (EI,	m/z):	 360	 (M+H).	 Anal.	 calcd.	 for	
C21H17N3O3:	 C,	 70.18;	 H,	 4.77;	 N,	 11.69.	 Found:	 C,	 70.16;	 H,	
4.74;	N,	11.70%.	HPLC:	r.t.	=	6.18	min,	purity	=	99.3%.	
3‐(Benzo[b]thiophen‐2‐yl)‐5,	 6‐dihydro‐6‐(3‐methoxyphen	
yl)‐1H‐pyrazolo[3,4‐c]pyridin‐7(4H)‐one	 (15b):	 Color:	 Yellow.	
Yield:	88%.	M.p.:	188‐189	°C.	 1H	NMR	(400	MHz,	DMSO‐d6,	δ,	
ppm):	3.40	(t,	2H,	J	=	8.4	Hz,	CH2),	3.74	(s,	3H,	O‐CH3),	4.24	(d,	
2H,	J	=	6.2	Hz,	N‐CH2),	6.38	(d,	1H,	J	=	7.6	Hz,	Ar‐H),	6.50	(s,	1H,	
Ar‐H),	6.63‐6.57	(m,	2H,	Ar‐H),	7.21‐7.11	(m,	3H,	Ar‐H),	7.56‐
7.44	(dd,	2H,	J	=	8.2	Hz,	4.1Hz,	Ar‐H)	14.4	(br,	1H,	NH).	13C	NMR	
(100	MHz,	CDCl3,	δ,	ppm):	13.54,	52.82,	55.65,	98.46,	104.31,	
104.61,	 108.66,	 111.12,	 121.18,	 122.34,	 123.76,	 124.44,	
128.84,	134.67,	150.42,	150.67,	156.8,	157.00,	161.73.	LC‐MS	
(EI,	m/z):	375	(M+H).	Anal.	calcd.	for	C21H17N3O2S:	C,	67.18;	H,	
4.56;	N,	11.19.	Found:	C,	67.16;	H,	4.58;	N,	11.18%.	HPLC:	r.t.	=	
7.63	min,	purity	=	99.7%.	
5,6‐Dihydro‐6‐(3‐methoxyphenyl)‐3‐(quinolin‐3‐yl)‐1H‐pyra	
zolo[3,4‐c]pyridin‐7(4H)‐one	 (15c):	 Color:	 Off	 white.	 Yield:	
91%.	M.p.:	193‐194	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	
3.21	 (br	 s,	 2H,	 CH2),	 3.83	 (s,	 3H,	O‐CH3),	 4.16	 (s,	 2H,	N‐CH2),	
6.93	(d,	1H,	J	=	7.8	Hz,	Ar‐H),	7.12	(d,	1H,	J	=	8	Hz,	Ar‐H),	7.18	
(s,	1H,	Ar‐H),	7.40	(m,	1H,	Ar‐H),	7.58	(t,	1H,	J	=	7.2	Hz,	Ar‐H),	
7.73	(t,	1H,	J	=	7.2	Hz,	Ar‐H),	7.84	(d,	1H,	J	=	7.6	Hz,	Ar‐H),	8.15	
(d,	1H,	J	=	7.6	Hz,	Ar‐H),	8.56	(s,	1H,	Ar‐H),	9.43	(s,	1H,	Ar‐H),	
14.8	 (br,	 1H,	 NH).	 13C	 NMR	 (CDCl3,	 100	 MHZ):	 12.22,	 49.44,	
52.46,	 55.46,	 97.80,	 102.21,	 106.60,	 127.34,	 127.84,	 128.22,	
128.42,	 128.88,	 129.62,	 129.41,	 130.71,	 130.85,	 145.21,	
148.63,	 150.60,	 168.16.	 LC‐MS	 (EI,	 m/z):	 371	 (M+H).	 Anal.	
calcd.	 for	 C22H18N4O2:	 C,	 71.34;	 H,	 4.90;	 N,	 15.13.	 Found:	 C,	
71.32;	 H,	 4.91;	 N,	 15.14%.	 HPLC:	 r.t.	 =	 7.20	 min,	 purity	 =	
99.3%.	
5,	 6‐Dihydro‐6‐(3‐methoxyphenyl)‐3‐(quinolin‐5‐yl)‐1H‐
pyrazolo[3,4‐c]pyridin‐7(4H)‐one	(15d):	Color:	Off	white.	Yield:	
92%.	M.p.:	206‐207	°C.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	
3.75	(s,	3H,	O‐CH3),	3.80	(d,	2H,	J	=	7.6	Hz,	CH2),	4.38	(d,	2H,	J	=	
7.8	Hz,	N‐CH2),	6.38	(t,	1H,	J	=	7.6	Hz,	Ar‐H),	6.58	(s,	1H,	Ar‐H),	
6.65	(t,	1H,	J	=	7.8	Hz,	Ar‐H),	7.14	(m,	1H,	Ar‐H),	7.88	(m,	1H,	
Ar‐H),	8.14‐7.98	(m,	3H,	Ar‐H),	8.37‐8.33	(d,	1H,	J	=	7.8	Hz,	Ar‐
H),	 9.16	 (s,	 1H,	 Ar‐H),	 12.9	 (s,	 1H,	 NH).	 13C	 NMR	 (100	MHz,	
CDCl3,	 δ,	 ppm):	 12.62,	 49.44,	 52.56,	 54.46,	 97.76,	 102.31,	
106.76,	 127.44,	 127.84,	 128.32,	 128.42,	 128.88,	 129.42,	
129.40,	130.60,	130.85,	145.31,	148.63,	152.14,	168.60.	LC‐MS	
(EI,	m/z):	371	(M+H).	Anal.	calcd.	 for	C22H18N4O2:	C,	71.34;	H,	
4.90;	N,	15.13.	Found:	C,	71.31;	H,	4.92;	N,	15.11%.	HPLC:	r.t.	=	
7.81	min,	purity	=	96.1%.	
3‐(Benzofuran‐2‐yl)‐5,6‐dihydro‐6‐(pyrimidin‐2‐yl)‐1H‐pyra	
zolo[3,4‐c]pyridin‐7(4H)‐one	 (15e):	 Color:	 Yellow.	 Yield:	 79%.	
M.p.:	176‐177	 °C.	 1H	NMR	 (400	MHz,	DMSO‐d6,	 δ,	ppm):	3.22	
(q,	2H,	CH2),	4.24	(d,	2H,	 J	=	8.2	Hz,	N‐CH2),	7.41‐7.16	(m	4H,	
Ar‐H),	7.78‐7.61	(m,	2H,	Ar‐H),	8.84	(d,	2H,	 J	=	7.8	Hz,	Ar‐H),	
14.4	 (br,	 1H,	NH).	 13C	NMR	 (100	MHz,	 CDCl3,	 δ,	 ppm):	 10.24,	
43.92,	102.84,	110.36,	111.62,	116.21,	121.26,	123.36,	124.82,	
133.11,	 133.26,	 150.45,	 156.46,	 158.10,	 169.32.	 LC‐MS	 (EI,	
m/z):	332	(M+H).	Anal.	calcd.	for	C18H13N5O2:	C,	65.25;	H,	3.95;	
N,	21.14.	Found:	C,	65.23;	H,	3.97;	N,	21.15%.	HPLC:	r.t.	=	5.17	
min,	purity	=	99.6%.	
3‐(Benzo[b]thiophen‐2‐yl)‐5,	6‐dihydro‐6‐(pyrimidin‐2‐yl)‐
1H‐pyrazolo[3,4‐c]pyridin‐7(4H)‐one	 (15f):	 Color:	 Yellow.	
Yield:	84%.	M.p.:	202‐203	°C.	 1H	NMR	(400	MHz,	DMSO‐d6,	δ,	
ppm):	3.48	(q,	2H,	CH2),	4.44	(d,	2H,	 J	=	8.2	Hz,	N‐CH2),	7.48‐
7.16	(m	4H,	Ar‐H),	7.78‐7.38	(m,	2H,	Ar‐H),	8.84	(d,	2H,	J	=	7.6	
Hz,	 Ar‐H),	 14.3	 (br,	 1H,	 NH).	 13C	 NMR	 (100	 MHz,	 CDCl3,	 δ,	
ppm):	 10.24,	 43.92,	 102.84,	 110.36,	 111.62,	 116.21,	 121.26,	
123.36,	 124.82,	 133.11,	 133.26,	 150.45,	 156.46,	 158.10,	
169.32.	 LC‐MS	 (EI,	 m/z):	 347	 (M+H).	 Anal.	 calcd.	 for	
C18H13N5OS:	 C,	 62.23;	 H,	 3.77;	 N,	 20.16.	 Found:	 C,	 62.21;	 H,	
3.76;	N,	20.18%.	HPLC:	r.t.	=	8.12	min,	purity	=	98.1%.	
5,	 6‐Dihydro‐6‐(pyrimidin‐2‐yl)‐3‐(quinolin‐3‐yl)‐1H‐pyra	
zolo[3,4‐c]pyridin‐7(4H)‐one	(15g):	Color:	White.	Yield:	85%.	
M.p.:	211‐212	 °C.	 1H	NMR	 (400	MHz,	DMSO‐d6,	 δ,	ppm):	3.26	
(q,	2H,	 J=	7.6	Hz,	CH2),	4.26	(t,	2H,	 J	=	7.6	Hz,	N‐CH2),	7.38	(t,	
1H,	J	=	7.6	Hz,	Ar‐H),	7.6	(q,	1H,	J	=	8.2	Hz,	Ar‐H),	7.80	(t,	1H,	J	=	
8.2	Hz,	Ar‐H),	8.18‐8.02	(q,	2H,	Ar‐H),	8.6(s,	1H,	Ar‐H),	8.83	(d,	
2H,	 J	 =	Hz,	Ar‐H),	9.38	 (s,	1H,	Ar‐H),	14.1	 (br.	 s,	1H,	NH).	 	 13C	
NMR	 (100	MHz,	 CDCl3,	 δ,	 ppm):	 12.53,	 44.57,	 69.36,	 110.31,	
116.12,	 127,	 127.11,	 128.45,	 128.85,	 129.11,	 129.34,	 130.17,	
132.23,	 134.68,	 157.88,	 158.12.	 LC‐MS	 (EI,	m/z):	 343	 (M+H).	
Anal.	calcd.	for	C19H14N6O:	C,	66.66;	H,	4.12;	N,	24.55.	Found:	C,	
66.67;	 H,	 4.10;	 N,	 24.57%.	 HPLC:	 r.t.	 =	 8.42	 min,	 purity	 =	
98.0%.	
5,	 6‐Dihydro‐6‐(pyrimidin‐2‐yl)‐3‐(quinolin‐5‐yl)‐1H‐pyra	
zolo[3,4‐c]pyridin‐7(4H)‐one	 (15h):	 Color:	 White.	 Yield:	 80%.	
M.p.:	209‐210	 °C.	 1H	NMR	 (400	MHz,	DMSO‐d6,	 δ,	ppm):	2.80	
(q,	2H,	CH2),	4.20	(q,	2H,	N‐CH2),	7.36	(t,	1H,	J	=	7.2	Hz,	Ar‐H),	
7.40	(d,	1H,	J	=	7.4	Hz,	Ar‐H),	7.64	(d,	2H,	J	=	8	Hz,	Ar‐H),	7.81	
(t,	1H,	J	=	7.6	Hz,	Ar‐H),	8.12	(d,	1H,	J	=	7.4	Hz,	Ar‐H),	8.80	(d,	
2H,	J	=	7.6	Hz,	Ar‐H),	8.96	(s,	1H,	Ar‐H),	13.98‐14.2	(br.	s,	1H,	
NH).	13C	NMR	(100	MHz,	CDCl3,	δ,	ppm):	15.35,	45.33,	110.20,	
116.78,	 119.47,	 121.20,	 125.38,	 127.29,	 129.31,	 130.00,	
130.12,	 136.46,	 137.12,	 147.45,	 150.51,	 156.60,	 159.12,	
162.84.	 LC‐MS	 (EI,	m/z):	 343	 (M+H).	 Anal.	 calcd.	 for	 C19H14	
N6O:	 C,	 66.66;	 H,	 4.12;	 N,	 24.55.	 Found:	 C,	 66.67;	 H,	 4.11;	 N,	
24.54%.	HPLC:	r.t.	=	6.37	min,	purity	=	99.3%.	
	
2.3.	Biological	evaluation	
	
All	 the	 synthesized	 compounds	 were	 tested	 for	 their	 in	
vitro	anticancer	activity	against	various	cancer	cell	lines.		
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Table	1.	In	vitro	anticancer	screening	of	the	synthesized	compounds	against	five	cell	lines.	
Compound	 A‐549	a	 Si	f	 HeLa	b	 Si	f	 MCF‐7	c	 Si	f	 DU‐145	d	 Si	f	 HUVEC	e	
13a	 22.72±0.11	 4.04	 23.87±0.08 3.84 24.12±0.06 3.80 28.86±0.22 3.18	 91.8±0.28
13b	 15.81±0.11	 5.13	 14.32±0.04 6.74 26.32±0.06 3.67 33.73±0.12 2.86	 96.6±0.14
13c	 6.81±0.11	 12.73	 11.32±0.04 7.65 17.32±0.06 5.00 10.73±0.12 8.07	 86.6±0.28
13d	 10.65±0.11	 8.41	 18.79±0.22 4.76 16.86±0.12 5.31 20.82±0.11 4.30	 89.6±0.28
13e	 13.86±0.08	 6.39	 24.38±0.06	 3.63	 13.63±0.12	 6.50	 11.52±0.22	 7.69	 88.7±0.12	
13f	 15.72±0.11	 6.08	 26.87±0.08	 3.55	 24.12±0.06	 3.96	 38.86±0.22	 2.46	 95.6±0.28	
13g	 5.12±0.11	 17.42	 9.12±0.22	 9.78 9.36±0.12 9.52 13.52±0.11 6.59	 89.2±0.28
13h	 13.25±0.14	 6.53	 17.78±0.08	 4.87	 13.82±0.08	 6.26	 11.72±0.06	 7.38	 86.6±0.19	
15a	 10.82±0.11	 8.69	 13.39±0.22	 7.02	 11.36±0.12	 8.28	 9.52±0.11	 9.88	 94.1±0.26	
15b	 14.13±0.12	 6.18	 15.16±0.08 5.76 16.12±0.12 5.42 11.62±0.11 7.52	 87.4±0.22
15c	 23.86±0.08	 3.24	 14.38±0.06 6.50 20.63±0.12 4.53 11.52±0.22 8.12	 93.6±0.12
15d	 11.72±0.11	 7.81	 8.87±0.08	 10.32 13.12±0.06 6.98 18.86±0.22 4.85	 91.6±0.28
15e	 23.82±0.11	 3.55	 20.99±0.22 4.03 19.36±0.12 4.36 12.52±0.11 6.75	 84.6±0.28
15f	 10.78±0.14	 8.12	 18.78±0.08 4.66 14.82±0.08 5.91 18.72±0.06 4.67	 87.6±0.19
15g	 10.82±0.11	 8.78	 8.59±0.22	 11.07	 8.36±0.12	 11.37	 17.52±0.11	 5.42	 95.1±0.26	
15h	 9.13±0.12	 9.81	 14.16±0.08 6.32 6.12±0.12 14.17 11.62±0.11 7.71	 89.6±0.22
Doxil	 1.71±0.11	 51.57	 1.82±0.13	 48.46	 1.91±0.08	 46.17	 1.62±0.08	 54.44	 88.2±0.18	
a	A‐549:	Human	lung	cancer	cell	line.	
b	HeLa:	Human	cervical	cancer	cell	line	(ATCC	CCL‐2).	
c	MCF‐7:	Human	breast	cancer	cell	line.	
d	DU‐145:	Human	prostate	cancer	cell	line.	
e	HUVEC:	Human	umbilical	vein	endothelial	cell	line	(ATCC	CRL‐1730).	
f	Selectivity	Index	(SI)	=	IC50	of	pure	compound	in	normal	cell	line/IC50	of	same	compound	in	cancer	cell	line.	IC50	‐	The	concentration	required	to	inhibit	50%	of	
cell	population.	
	
	
The	anticancer	activity	test	 is	performed	according	to	the	
proce‐dure	 developed	 by	 the	 National	 Cancer	 Institute	 (NCI,	
USA)	 in	 the	 ‘In	 vitro	Anticancer	 Drug	 Discovery	 Screen’	 that	
uses	 the	 protein‐binding	 dye	 Sulforhodamine	 B	 (SRB)	 to	
assess	 cell	 growth	 [14,15].	Briefly,	 cells	 are	 grown	 in	96‐well	
plates	 in	 suspension	 and	 then	 exposed	 for	 48	 hours	 to	 four	
serial	 concentrations	 of	 1×10‐7,	 1×10‐6,	 1×10‐5,	 1×10‐4	 and	
1×10‐3	M	of	each	compound.	Cells	were	fixed	and	stained	with	
protein	binding	SRB	 stain.	Excess	 stain	 is	washed	 and	bound	
stain	 was	 solubilized,	 and	 the	 absorbance	 was	 measured	 at	
492	nm	in	a	plate	reader.	Concentration	of	the	compounds	that	
inhibited	50%	of	the	net	cell	growth,	growth	inhibition	of	50%	
(GI50),	was	calculated	 from	the	dose	response	curve	obtained	
for	each	test	compound	and	cell	line.	GI50	values	were	presen‐
ted	in	micro	molar	(μM)	concentration.	Doxorubicin	was	used	
as	 positive	 control	 for	 the	 comparison	 of	 cytotoxicity	 of	
synthesized	 compounds.	 Assays	were	 performed	 in	 triplicate	
on	three	 independent	experiments	and	their	mean	values	are	
taken	as	a	final	reading.	The	result	of	this	study	indicates	that	
compound	 13c,	 13g,	 15g	 and	 15h	 shows	 prominent	 anti‐
cancer	activity	 in	all	cell	 lines,	having	growth	inhibition	of	50	
(GI50)	 values	 of	 5.12	 to	 17.52	 µM	 (Table	 1).	 All	 experiments	
were	performed	in	duplicate	and	repeated	three	times.	
	
3.	Results	and	discussion	
	
3.1.	Chemistry	
	
In	Scheme	1,	Step	(a)	is	enamine	formation	which	is	done	
by	reacting	compound	1	with	DMF‐DMA	heating	at	100	°C	for	
obtaining	 compound	 2	 with	 78%	 yield.	 The	 compound	 2	 is	
reacted	 with	 N2H4.H2O	 in	 EtOH	 at	 80	 °C	 for	 8	 h	 to	 obtain	
compound	3	with	having	68.3%	yield.	The	structure	of	4,5,6,7‐
tetrahydro‐1H‐pyrazolo[4,3‐c]pyridine	is	confirmed	by	singlet	
at	δ	7.31	ppm	in	1H	NMR	[16].	Purification	of	the	compound	3	
required	 purification	 by	 using	 column	 chromatography.	 The	
overall	 yield	 obtained	 by	 this	method	 is	 greater	 than	 earlier	
reports	 [13].	 4,5,6,7‐Tetrahydro‐1H‐pyrazolo[4,3‐c]pyridine	
(3)	 is	 reacted	with	 di‐tert‐butyl	 dicarbonate	 (Boc	 anhydride)	
using	 triethylamine	 as	 base	 to	 obtain	 di‐tert‐butyl‐4,5‐di	
hydro‐7H‐pyrazolo[3,4‐c]pyridine‐1,6‐dicarboxylate	 (4)	 with	
yield	91%.	The	compound	4	is	having	BOC	protection	on	both	
nitrogen’s	confirmed	by	1H	NMR	showing	singlet	for	18	H	at	δ	
1.56	ppm.	The	Step	(d)	is	deportation	of	aliphatic	N‐BOC	which	
is	 achieved	 by	 treating	 compound	4	with	 2	N	HCl	 for	 2	 h	 to	
obtain	compound	5,	confirmed	by	1H	NMR	showing	singlet	for	
9	H	at	δ	1.56	ppm.	The	compound	5	was	treated	with	pyridine	
Br2	 at	 room	 temperature	 for	 3	h	 to	 obtain	 compound	6	with	
92%	 yield.	 The	 structure	 of	 tert‐butyl‐3‐bromo‐4,5,6,7‐tetra	
hydropyrazolo[3,4‐c]pyridine‐1‐carboxylate	 (6)	 was	 confir‐
med	by	disappearance	of	singlet	at	δ	7.31	ppm	in	1H	NMR.	The	
compound	6	 reacted	with	 aqueous	 NaOH	 in	 heating	 for	 3	 h.	
There	 is	 formation	 of	 compound	 7	 in	 88.4%	 yield	 which	 is	
confirmed	 by	 desired	 mass	 in	 LC‐MS.	 The	 compound	 7	 is	
protected	by	using	benzylbromide	in	THF	by	using	mixture	of	
bases	 as	 2,6‐leutidine	 and	 DMAP	 at	 room	 temperature	 for	
compound	6h	 to	obtain	compound	8	with	83%	yield,	with	1H	
NMR	 signals	 at	 δ	 7.38‐7.28	 ppm	 (m,	 5H).	 The	 compound	 8	
having	free	hydroxyl	group	which	is	protected	by	using	triflic	
anhydride	at	room	temperature	for	12	h	to	obtain	compound	9	
with	 88.5%	 yield.	 t‐Butyl	 3‐(2,2,2‐trifluoroacetoyloxy)‐6‐
benzyl‐4,5,6,7‐tetrahydropyrazolo[3,	 4‐c]pyridine‐1‐carboxy‐
late	 (9)	 is	 key	 intermediate	 for	 the	 synthesis	 of	 final	 com‐
pounds	13a‐h	 and	15a‐h.	The	 compound	9	was	 treated	with	
different	 aromatic	 boranic	 acids	 at	 100	 °C	 for	 6	 h	 to	 obtain	
compounds	 10a‐d	 with	 yields	 in	 the	 range	 from	 63	 to	 83%	
yields	after	purifications	by	silica	gel	(100‐200	mesh)	column	
chromatography.	 Debenzylation	 of	 compounds	 10a‐d	 was	
done	by	using	Pd/C	in	EtOH	for	50	psi	of	hydrogen	for	3	h	at	
room	 temperature	 to	 obtain	 compounds	 11a‐d	 with	 84	 to	
90%	yields.	Alkylation	of	compounds	11a‐d	was	done	by	using	
substituted	 aromatic	 bromides	 in	 THF	 by	 using	mixed	 bases	
2,6‐leutidine	and	DMAP	for	3	h	at	room	temperature	to	obtain	
compounds	 12a‐h	 with	 yields	 84	 to	 93%.	 The	 cleavage	 of	
protecting	 group	 of	 compounds	 12a‐h	 was	 done	 by	 using	
aqueous	 6	 N	 HCl	 at	 room	 temperature	 for	 6	 h	 to	 obtain	
compounds	 13a‐h	 with	 yields	 76	 to	 91%.	 The	 mixed	 bases	
used	 in	 Steps	 (g)	 and	 (k)	 to	 enhance	 the	 reactivity	 of	
secondary	amine	used	for	reaction.	
In	Scheme	2,	compounds	12a‐h	are	treated	with	KMnO4	in	
DCM	and	18‐crown‐6	used	as	phase	transfer	catalyst	at	room	
temperature	 for	6	h	 to	give	compounds	14a‐h	with	yields	71	
to	78%,	which	is	confirmed	by	vanishing	singlet	at	3.78	in	1H	
NMR.	The	compound	14a‐h	are	converted	to	compounds	15a‐
h	by	using	aqueous	6	N	HCl	at	room	temperature	for	6	h	with	
79	 to	92%	yields.	The	 final	compounds	13a‐h	 and	15a‐h	 are	
obtained	 with	 reaction	 yields	 76	 to	 92%.	 Purity	 of	 all	 final	
compounds	and	key	intermediates	is	>95%	which	are	further	
used	for	biological	activity	studies.	
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Table	2.	Inhibitory	activity	of	compound	13c,	13g,	15g	and	15h	against	panel	of	eight	human	kinases.	
Kinase	 %	Inhibition	
Compound	13c	 Compound	13g Compound	15g Compound	15h	
Aurora‐A	 73	 64 51 57	
Aurora‐B	 41	 70 77 73	
CDK2/cyclinA	 28	 37 23 33	
CDK2/cyclinE	 17	 22 21 23	
CDK5/P25	 66	 59 70 56	
EGFR	 14	 21 15 18	
mTOR	 44	 68 46 48	
PDK1	 23	 28	 19	 33	
	
	
3.2.	Biological	studies	
	
All	 the	 newly	 synthesized	 compounds	 13a‐h	 and	 15a‐h	
were	 evaluated	 for	 their	 antiproliferative	 activities	 against	 a	
panel	 of	 four	 different	 human	 cancer	 cell	 lines.	 The	 IC50	 for	
each	 synthesized	 compounds	 are	 calculated	 with	 respect	 to	
one	human	normal	cell	line	Human	umbilical	vein	endothelial	
cell	 line	 (ATCC	 CRL‐1730)	 and	 results	 are	 summarized	 in	
Table	1.	These	values	represent	the	concentration	required	to	
inhibit	 50%	 cell	 population	 compared	 with	 the	 control	 cells	
treated	 with	 DMSO	 and	 positive	 control	 Doxorubicin	 under	
similar	conditions.		
From	 substituted	 tetra‐hydro‐6‐(substituted)‐1H‐pyra‐
zolo[3,4‐c]pyridine	 derivatives	 (13a‐h	 and	 14a‐h),	 the	 IC50	
value	ranges	from	5.12	to	38.86	µM	all	four	cell	lines.	For	cell	
line	 A‐549,	 compound	 13g	 is	 most	 active	 with	 IC50	 value	 of	
5.12	µM;	 and	 compound	13c	 is	 also	 active	with	 IC50	 value	of	
6.81	µM	along	with	compounds	13b,	13e,	13f,	13h,	15b	and	
15d	 are	 moderately	 active	 with	 IC50	 value	 of	 15.81,	 13.86,	
15.72,	 13.25,	 14.13	 and	 11.72	 µM,	 respectively.	 The	 com‐
pounds	13a,	15c	and	15e	are	most	inactive	compounds	in	the	
series.	 For	cell	 line	HeLa,	 it’s	have	 IC50	values	are	 in	between	
8.59	to	26.87	µM.	The	compounds	15g	is	most	active	with	IC50	
value	of	8.59	µM	along	with	compound	15d	and	13g	with	IC50	
values	of	8.87	and	9.12	µM,	respectively.	The	compounds	13b,	
13c,	15a,	15c	and	15h	are	moderately	active	with	IC50	values	
ranging	in	between	11.32	to	14.38	µM.	Remaining	compounds	
are	 less	active	with	 IC50	value	 in	between	15.16	 to	26.87	µM.	
For	cell	line	MCF‐7,	the	IC50	values	are	in	the	range	of	6.12	and	
26.32	µM.	The	compounds	15h,	15g	and	13g	are	most	active	
IC50	 values	 of	 6.12,	 8.63	 and	 9.36	 µM,	 respectively,	 total	 five	
compounds	are	moderately	active	with	IC50	values	in	the	range	
of	11.36	to	14.82	µM	and	eight	compounds	are	less	active	with	
IC50	values	are	in	the	range	of	16.12	to	26.32	µM.	For	cell	line	
DU‐145,	 the	 IC50	 value	 ranges	 from	 9.52	 to	 38.56	 µM.	 The	
compounds	15a	is	most	active	with	IC50	value	of	9.52	µM	along	
with	 compound	13c	 having	 IC50	 value	 of	 10.37	 µM	 are	most	
active.	The	compounds	13e,	13h,	15b,	15c,	15d,	15h	and	15e	
are	also	active	compounds	in	DU‐145	cell	line	with	IC50	values	
in	the	range	of	10‐12	µM	total	seven	compounds	are	less	active	
with	IC50	values	in	the	range	of	13.52	to	38.56	µM.		
Compound	13a	having	3‐methoxy	phenyl	and	benzofuran‐
2‐yl	 groups	 is	 inactive	 compared	 with	 standard	 with	 IC50	
values	 in	 the	 range	 of	 22.72	 to	 28.87	 µM	 in	 all	 cell	 lines.	
Compound	13b	 is	moderately	 active	with	 IC50	 value	 of	 14.33	
µM	of	HeLa	cell	line	and	in	remaining	all	cell	lines	it	is	inactive.	
The	compound	13c	is	active	in	A‐549	cell	line	and	DU‐145	and	
is	moderately	active	 in	HeLa	and	 it	 is	most	 inactive	 in	MCF‐7	
due	 to	 presence	 of	 3‐methoxy	 phenyl	 and	 3‐yl	 quinolone	
groups.	The	compound	13d	is	moderately	active	in	A‐549	and	
in	remaining	cell	lines,	it	is	inactive.	Compound	13e	is	inactive	
in	cell	 lines	HeLa	and	 in	remaining	cell	 lines,	 it	 is	moderately	
active	 with	 IC50	 values	 11.82	 to	 13.86	 µM,	 its	 having	
pyrimidine	 and	 benzo‐furan	 group.	 Compound	13f	 is	mostly	
inactive	in	all	cell	lines	because	the	presence	of	pyrimidine	and	
benzo‐thiophene	 group.	 The	 compound	 13g	 is	 active	 com‐
pound	 in	all	 cell	 lines	with	 IC50	values	 in	 the	range	of	5.12	 to	
9.36	 µM	 and	 for	 DU‐145,	 it	 is	 moderately	 active	 with	 IC50	
values	of	13.52	µM	due	to	the	presence	of	pyrimidine	and	3‐yl	
quinolone	group.	Compound	13h,	for	HeLa	cell	line,	is	inactive	
with	 IC50	value	of	17.78	µM	and,	 for	remaining	cell	 lines,	 it	 is	
moderately	 active	 with	 IC50	 values	 in	 the	 range	 of	 11.72	 to	
13.82	 µM	 due	 to	 presence	 of	 pyrimidine	 and	 5‐yl‐quinolone	
group.	 The	 compound	 15a	 having	 3‐methoxy	 phenyl	 and	
benzofuran‐2‐yl	groups	are	mostly	active	 in	all	cell	 lines	with	
IC50	values	 in	 the	range	of	10.82	 to	13.39	µM	and	 is	active	 in	
DU‐145	 with	 IC50	 value	 of	 9.52	 µM.	 The	 compound	 15b	 is	
moderately	 active	 in	 A‐549	 and	 DU‐145	 cell	 lines	 and	 it	 is	
inactive	 in	 HeLa	 and	 MCF‐7	 cell	 line.	 The	 compound	 15c	 is	
moderately	 active	 in	 HeLa	 and	 DU‐145	 (IC50	 value	 of	 11.52	
µM)	 cell	 lines	 and	 it	 is	 inactive	 in	 A‐549	 and	MCF‐7	 cell	 line	
23.86	and	20.63	µM,	respectively.	The	compound	15d	is	active	
for	 HeLa	 cell	 line	 with	 IC50	 value	 of	 8.87	 µM	 and	 it	 is	 also	
moderately	 active	 for	A‐549	with	 IC50	 value	 of	 11.72	µM,	 for	
MCF‐7	 cell	 line	 with	 IC50	 value	 of	 13.12	 µM	 with	 moderate	
active	interestingly	it	is	in	active	for	DU‐145	cell	line	with	IC50	
value	of	18.86	µM.	The	compound	15e	having	pyrimidine	and	
benzo‐furan	 group	 is	 moderately	 active	 for	 DU‐145	 cell	 line	
with	 IC50	value	of	12.52	µM	and	 for	 remaining	cell	 lines,	 it	 is	
inactive.	The	compound	15f	having	IC50	values	of	10.78	µM	is	
active	for	A‐549	cell	line	and	it	is	inactive	for	remaining	all	cell	
lines	with	IC50	values	of	14.82	to	18.78	µM.	The	compound	15g	
is	active	for	A‐549,	HeLa	and	MCF‐7	cell	lines	with	IC50	values	
of	10.82,	8.59	and	8.36	µM,	respectively.	It	is	inactive	with	DU‐
145	cell	line	with	IC50	value	of	17.52	µM	with	pyrimidine	and	
3‐yl‐quinolone	groups.	The	compound	15h	having	pyrimidine	
and	 5‐yl‐quinolone	 groups	 is	 most	 active	 in	 MCF‐7	 cell	 line	
with	IC50	value	of	6.12	µM	and	A‐549	with	IC50	value	of	9.13	µM	
also	it	is	moderately	active	in	HeLa	and	DU‐145	cell	lines	with	
IC50	values	of	14.16	and	11.62	µM,	respectively.	From	cell	line	
data	compounds	13c,	13g,	15g	and	15h	are	most	active	which	
are	having	pyrimidine‐2‐yl	group	and	quinoline3/5‐yl	groups,	
compared	 with	 compounds	 having	 3‐methoxy	 phenyl,	
benzofuran	and	benzothiophene	groups.	The	compound	13c	is	
more	active	than	compound	13d	as	both	of	these	compounds	
are	separated	by	position	of	nitrogen	in	the	qunioline	ring,	the	
3‐methoxy	 compounds	with	 benzofuran	 and	 benzothiophene	
are	 less	 active	 than	 compounds	 having	 pyrimidine‐2‐yl	
substitutions.	 Interestingly	 compounds	 having	 substituted	
4,5,6,7‐tetrahydro	 group	 and	 substituted	 5,6‐dihydro	 groups	
are	 moderate	 to	 active	 on	 all	 four	 cell	 lines	 and	 that	
substituted	 5,6‐dihydro	 groups	 are	 more	 active	 than	 that	 of	
substituted	 4,5,6,7‐tetrahydro	 group.	 These	 are	 results	 from	
both	 series	 of	 compounds.	 There	 is	 not	 much	 difference	 in	
their	 inhibitions	 in	all	 four	cancer	 cell	 lines.	Further	we	have	
studied	the	most	active	compounds	13c,	13g,	15g	and	15h	on	
human	kinases.	
The	compounds	13c,	13g,	15g	and	15h	are	most	active	in	
cell	 line	 studies,	 so	 further	 we	 have	 tested	 for	 its	 activity	
against	a	panel	of	eight	human	kinase	at	10	µM	concentrations.	
For	 Aurora‐A	 kinase	 compounds,	 they	 shows	 73,	 64,	 51	 and	
57%	 inhibitions,	 respectively.	 The	 results	 are	 summarized	 in	
Table	2.	For	Aurora‐B	kinase,	compound	13c	shows	41%	inhi‐
bitions	and	for	remaining	compounds	13g	 (70%),	15g	 (77%)	
and	 15h	 (73%)	 inhibitions.	 For	 CDK/cyclinA,	 CDK/cyclinE,	
EGFR	 and	PDK1,	 the	 inhibition	 is	 in	 the	 range	 of	 17	 to	 37%.	
CDK5/P25	 kinase	 and	mTOR	 kinase	 the	 inhibitions	 are	 in	 the	
range	 of	 44	 to	 70%.	 For	 Aurora‐A,	 Aurora‐B,	 CDK5/P25	 and	
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mTOR	kinase,	all	the	compounds	shows	promising	inhibitions	
to	great	extent.	The	inhibition	results	shows	compound	13c	is	
active	for	aurora‐A	kinase	and	CDK5/P25	kinase	and	it	shows	
less	 inhibition	 for	 remaining	 kinases.	 Compounds	 13g,	 15g	
and	 15h	 shows	 >50%	 inhibitions.	 For	 EGFR,	 PDK1,	 CDK2/	
cyclinE	and	CDK2/cyclinA	kinases,	most	of	compounds	shows	
<40%	inhibitions.	
	
4.	Conclusion	
	
We	have	synthesized	3‐(substituted)‐4,5,6,7‐tetrahydro‐6‐
(substituted)‐1H‐pyrazolo[3,	 4‐c]pyridine	 (13a‐h)	 and	 3‐(	
substituted)‐5,	 6‐dihydro‐6‐(substituted)‐1H‐pyrazolo[3,	 4‐c]	
pyridin‐7(4H)‐one	 (15a‐h).	 The	 synthesis	 mainly	 required	
protection,	 deportation,	 N‐alkylation	 and	 Suzuki	 coupling	
reactions.	We	have	 optimized	 all	 the	 steps	 for	 clean	 reaction	
profile	 and	 easy	 isolation	 of	 all	 intermediates	 and	 final	 com‐
pounds.	The	compounds	13a‐h	and	15a‐h	are	tested	for	anti‐
proliferative	 activity	 on	 panel	 of	 four	 cell	 lines.	 Compounds	
with	 pyrimidine‐2‐yl	 substitutions	 and	 quinolone	 3/5‐yl	
groups	are	most	active	compared	with	3‐methoxy	and	benzo‐	
furane/benzothiophene.	 Compounds	 13c,	 13g,	 15g	 and	 15h	
are	 tested	 for	 panel	 of	 eight	 kinase	 inhibitors	 and	 most	 of	
derivatives	 are	 mostly	 active	 on	 Aurora‐A,	 Aurora‐B,	
CDK5/P25	and	mTOR	human	kinase	inhibitors.	
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